Neutrophils Actively Contribute to Obesity-Associated Inflammation and Pathological Complications

Eileen Uribe-Querol 1 and Carlos Rosales 2,*

1 Laboratorio de Biología del Desarrollo, División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; euquerol@fo.odonto.unam.mx
2 Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
* Correspondence: carosal@unam.mx

Abstract: Obesity is characterized by an increase in body weight associated with an exaggerated enlargement of the adipose tissue. Obesity has serious negative effects because it is associated with multiple pathological complications such as type 2 diabetes mellitus, cardiovascular diseases, cancer, and COVID-19. Nowadays, 39% of the world population is obese or overweight, making obesity the 21st century epidemic. Obesity is also characterized by a mild, chronic, systemic inflammation. Accumulation of fat in adipose tissue causes stress and malfunction of adipocytes, which then initiate inflammation. Next, adipose tissue is infiltrated by cells of the innate immune system. Recently, it has become evident that neutrophils, the most abundant leukocytes in blood, are the first immune cells infiltrating the adipose tissue. Neutrophils then get activated and release inflammatory factors that recruit macrophages and other immune cells. These immune cells, in turn, perpetuate the inflammation state by producing cytokines and chemokines that can reach other parts of the body, creating a systemic inflammatory condition. In this review, we described the recent findings on the role of neutrophils during obesity and the initiation of inflammation. In addition, we discuss the involvement of neutrophils in the generation of obesity-related complications using diabetes as a prime example.

Keywords: neutrophil; obesity; adipose tissue; inflammation; diabetes; neutrophil-to-lymphocyte ratio; macrophage; microbiota

1. Introduction

Obesity is a clinical condition defined as a lopsided body weight associated with an exaggerated enlargement of the adipose tissue [1,2]. In simple terms, obesity appears when people have low physical activity (a sedentary lifestyle) and increased ingestion of food, particularly of high-energy-yielding groceries [3]. However, obesity is more complex than an imbalance between caloric intake and energy requirements. External factors, such as genetics, socioeconomic status, and environment, influence food consumption, nutrient assimilation, thermogenesis, and fat storage in various adipose tissues [4]. At the present time, 39% of the world population is obese or overweight. The prevalence of these conditions has steadily increased globally during the last 30 years [5], and it is expected that, if this tendency continues, by 2025, obesity prevalence in the world will be 18% in men and 21% in women [6]. This tendency makes obesity the 21st century epidemic [7,8] with an important economic burden on health costs because obesity is associated with the development of multiple pathological conditions also known as obesity-related complications, including type 2 diabetes mellitus, cardiovascular diseases, some types of cancer, and coronavirus disease 2019 (COVID-19) [3,9–11].

Obesity is also characterized by a mild, chronic, systemic inflammation. The excessive accumulation of fat in the adipose tissue is due to either an increase in adipocyte size...
(hypertrophy) or the growth of new adipocytes (hyperplasia). Both conditions cause adipocyte stress and malfunction leading to inflammation [12]. As obesity worsens, the initial mild (low-grade) inflammation becomes chronic, and later it turns systemic [13–15]. The adipose tissue is composed not only of adipocytes (mature fat cells), but also of different types of immune cells, which are important for tissue homeostasis [16,17]. During obesity, stressed adipocytes produce adipokines, which recruit and activate innate immune cells [18]. These immune cells in turn perpetuate the inflammation state via production of cytokines and chemokines that can even influence other parts of the body, creating a systemic inflammatory condition [19,20].

The vast majority of immune cells infiltrating the adipose tissue are macrophages [21,22]. These immune cells accumulate around adipocytes in crown-like structures [23] where macrophages can proliferate and further maintain the adipose tissue inflammation [24]. However, recently it has become evident that neutrophils, the most abundant leukocytes in blood and the primary effector cells of acute inflammation, are also the first immune cells infiltrating the adipose tissue [25]. Neutrophils then get activated [26–28] and release multiple inflammatory factors and chemokines that recruit macrophages and other immune cells including B cells, T cells, and NK cells [29]. The crosstalk between adipocytes and neutrophils further promotes the adipose tissue inflammation [30]. In this review, we describe the recent findings on the role of neutrophils during obesity and the initiation of a low-grade systemic inflammation. In addition, we discuss the involvement of neutrophils in the generation of obesity-related complications using diabetes as a prime example.

2. Obesity

Obesity is associated not only with an excessive accumulation of fat in the adipose tissue [1,2], but also with a mild, chronic, systemic inflammation [12]. Increased fat accumulation results from an imbalance between the energy derived from food ingestion and the energy used for body functions. However, this simple view (based on thermodynamics) does not take into consideration the complexity of body weight control. Body weight is influenced not only by the quality of the diet and the amount of physical activity, but also by work schedules, ambient temperature, lack of sleep; drugs that modify endocrine and reproductive functions, gut microbiota, and epigenetic effects [4]. The complexity of weight control makes the etiology of obesity an intricate mix of personal choices, socioeconomic level, and environmental factors [2]. As a result, obesity has become a pandemic health problem [7,8]. In 2016, the World Health Organization (WHO) estimated that more than 1.9 billion people, 18 years and older, were overweight. Of these, over 650 million were obese. In addition, over 340 million children and adolescents aged 5–19 were also overweight or obese [31].

Assessment of obesity is not easy since there are multiple ways to accumulate fat in tissues. This variation creates two principal types of obesity: subcutaneous and visceral. In subcutaneous obesity (which is more common in women), excess fat is found under the skin surrounding the hip and thigh areas, while in visceral obesity (which is more common in men), fat is concentrated in the abdominal region, primarily in the mesenteric adipose tissue. In order to assess obesity, several indicators have been used. The body mass index (BMI) is one such indicator that estimates overweight and obesity based on the weight of the individual expressed in kilograms (kg) divided by the square height of the individual in meters (m$^2$) [31]. In addition, other indicators besides the BMI should be considered to fully assess the severity of obesity. For example, waist circumference helps to discriminate between subcutaneous obesity and visceral obesity, and it is a good indicator of poor health. A strong correlation of waist circumference with all-cause mortality was found for men (with waist circumferences larger than 110 cm) and for women (with waist circumferences larger than 95 cm) [32].

Obese individuals are at a greater risk of developing numerous health problems that play a role in premature death [5,31,32], including features of the metabolic syndrome [1,33], and other obesity-related complications such as type 2 diabetes mellitus, cardiovascular
diseases, some types of cancer [3], and COVID-19 [11]. In addition, obesity has a negative influence on psychological and cognitive functions [34,35].

3. Microbiota and Obesity

Obesity is usually accompanied by a mild, chronic, systemic inflammation. This inflammatory state is initiated by damage to the adipose tissue due to excessive fat deposition (see later), and also by increased intestinal permeability due to alterations to the gut microbiota [36]. The gut microbiota is the community of microorganisms (including bacteria, archaea, fungi, protozoa, and viruses) that reside in the digestive tract. The dominant phyla in the gut are Firmicutes (Gram-positive) (60–65%), Bacteroidetes (Gram-negative) (20–25%), Proteobacteria (such as Escherichia and Enterobacteriaceae) (10%), and Actinobacteria (Gram-positive) (3%) [37,38].

Recent years have seen an increasing evidence of the association of changes in gut microbiota with the development of obesity (reviewed in [39–43]). This association was evidenced through initial reports showing that germ-free mice fed a high-fat diet had reduced body fat and did not develop obesity [44,45]. However, these mice recuperated fat and developed insulin resistance and glucose intolerance after reconstitution with the gut microbiota from normal mice [45]. Then, a metagenomic analysis showed that the two main bacterial phyla, Firmicutes and Bacteroidetes [37], maintain a relatively constant balance both in lean mice and humans; but in obese individuals, higher levels of Firmicutes and lower levels of Bacteroidetes were found [46,47]. Interestingly, after eliminating the high-fat diet, the ratio of Firmicutes/Bacteroidetes was reverted to the levels found in lean individuals [46]. Most other studies have had similar results [40]. However, numerous reports of opposite results suggest that the Firmicutes/Bacteroidetes ratio not always increases in obesity, and thus, further studies are required to resolve this issue [48]. Nevertheless, it seems that changes in specific bacteria, more than the ratio of the phyla, are better associated with obesity [49].

Altering the gut microbiota composition has important metabolic consequences. For example, obesity-associated microbiotas have been found to be more efficient at obtaining energy from the diet by producing enzymes that degrade food more efficiently, thus favoring a larger caloric intake [47]. Another significant consequence of an altered microbiota during obesity is the increased intestinal permeability [50], which leads to the escape of bacteria and bacterial products across the intestinal barrier into the blood circulation [36]. A major bacterial product found to cross the intestinal barrier in obese individuals is lipopolysaccharide (LPS), which triggers innate immune cells, leading to inflammation [51,52]. A high-fat diet increases the growth of Gram-negative bacteria and promotes LPS absorption across the intestinal barrier [51,53]. Thus, LPS absorption caused by ingestion of high-fat diets is related to obesity-induced low-grade systemic inflammation [54].

In contrast, other bacterial products such as short-chain fatty acids (SCFAs) have been associated with maintenance of reduced weight [55]. SCFAs, predominantly butyrate, acetate, and propionate, are produced by fermentation of nondigestible carbohydrates (dietary fiber) by various gut bacteria [56] and serve as an energy source for the colonic epithelia (butyrate), liver (propionate), and peripheral tissues (acetate) [57]. In particular, butyrate and propionate induce the production of gut hormones, such as hormone peptide tyrosine (PYY) and glucagon-like peptide-1 (GLP-1) from colonic L cells [58] via their cognate free fatty acid receptors (FFARs) [59]. In this way, SCFAs lead to reduced food intake, resulting in weight loss and the maintenance of reduced weight [50,59,60]. In addition, SCFAs can diminish inflammation by modulating several leukocyte functions, including reduced production of inflammatory cytokines and eicosanoids, inhibition of leukocyte migration to inflammation sites [61], and induction of neutrophil apoptosis [62].

Based on the evidence that microbiota composition can modulate body weight and inflammation, a growing interest exists to modify the gut microbiota by different approaches. The use of probiotics (live microorganisms which in proper quantities could provide a
health benefit) or of prebiotics (nondigestible food ingredients that favor growth of health-promoting bacteria) has been extensively tried [63-65]. Furthermore, fecal microbiota transplantation is now considered as a feasible therapy for treating obesity by influencing the composition of the gut microbiota [66]. Although some reports suggest that these approaches can reduce obesity and other associated complications [41,67], in general, only a limited success is achieved by microbiota-related interventions for body weight control in humans [68]. Therefore, future research is needed combining different approaches to improve the beneficial effects of microbiota modification on obesity.

Nevertheless, it is clear that an altered microbiota during obesity can induce a low-grade systemic inflammation by increasing intestinal permeability [50] and allowing bacterial products, such as LPS, to cross the intestinal barrier into the blood circulation [36].

4. Changes of the Adipose Tissue during Obesity

There are two principal types of adipose tissue: brown adipose tissue and white adipose tissue. Together, these tissues are involved in maintaining the energy balance of the body [69]. Adipocytes (adipose cells) in brown adipose tissue are involved in the regulation of body temperature by generating heat (thermogenesis) using lipid reserves. This tissue is abundant in newborn babies and is found in the interscapular and supraclavicular regions, and around critical organs such as the heart, the kidneys, the trachea, and the pancreas. It is believed that this anatomical distribution of brown adipose tissue is important for protecting vital organs from hypothermia [70]. Brown adipose tissue is present not only in newborns, but also in adult humans, and its mass correlates with leanness [71]. White adipose tissue is the most abundant one throughout the body of adult humans. The main function of this tissue is the storage of energy in the form of lipids (triglycerides). However, recent studies have shown that adipocytes not only accumulate fat, but also are capable of secreting bioactive substances, collectively known as adipocytokines or adipokines [72,73]. In addition, a third type of adipose tissue is also found within white adipose tissue. This minor type is known as “beige” or “brite” adipose tissue, and it is also involved in thermogenesis [69,71]. As mentioned before, adipose tissues are also classified according to their location in the body as subcutaneous or visceral. Visceral adipose tissue is more cellular (adipocytes) and vascular than subcutaneous tissue and contains more immune cells (see later) [74]. Visceral adipose tissue is of particular interest because accumulation of fat in this tissue correlates with the development of the metabolic syndrome [75].

During obesity, the principal change observed in adipose tissue is the accumulation of fat. As a result of energy surplus, adipose tissues must store more lipids. This is achieved by first inducing adipose tissue hyperplasia. The increased number of adipocytes expands the tissue, which then serves as a “metabolic sink” distributing the excess fat in the growing tissue. Later, when the tissue cannot expand anymore (due to causes that are not well-identified), stored lipids (triglycerides) induce adipocyte hypertrophy. Adipocytes enlarge until they become saturated and are no longer functional [2] (Figure 1).

In addition, when adipose tissue has no more room for storing the excess of triglycerides, an abnormal deposition of lipids begins to appear in other normally lean tissues, such as the heart, the liver, and the kidneys. This event is known as ectopic fat deposition [75], and it has harmful effects on metabolism, including insulin sensitivity and dyslipidemia (high levels of triglycerides or low levels of high-density lipoprotein cholesterol) [76,77]. Interestingly, visceral obesity is more frequently associated with ectopic fat deposition than subcutaneous obesity [78].
Figure 1. Changes in the adipose tissue. (a) In normal adipose tissue, adipocytes store limited amounts of fat (triglycerides). Some anti-inflammatory M2 macrophages are distributed throughout the tissue. (b) In obese adipose tissue, adipocytes accumulate excessive amounts of fat and become larger and stressed. These adipocytes then become dysfunctional, releasing proinflammatory adipokines that recruit and activate more macrophages into the tissue. Macrophage activation results in an increase in macrophages with the M1 (proinflammatory) phenotype and a decrease in M2 (anti-inflammatory) macrophages. Due to hypoxia and stress, adipocytes also become apoptotic. Macrophages concentrate around apoptotic and dead adipocytes, forming crown-like structures where defective adipocytes are eliminated by phagocytosis.

Adipocytes with excessive lipid storage become severely stressed. The increase in size is tolerated up to a certain (threshold) point, beyond which adipocytes develop molecular alterations resulting in dysfunction and death [79]. Interestingly, visceral adipocytes become dysfunctional at a smaller size than subcutaneous adipocytes [21]. This fact may explain why visceral obesity is clearly associated with obesity-related complications. An important molecular alteration observed in dysfunctional adipocytes is the endoplasmic reticulum (ER) stress response, which is activated by incorrectly folded proteins within the ER [80], and it is connected to inflammatory pathways [81]. Another molecular alteration observed in stressed adipocytes is the response to hypoxia. As adiposity becomes severe, lower levels of oxygen are present in adipose tissues. This results in activation of the hypoxia-inducible factor (HIF) signaling cascade, which in turn upregulates proinflammatory responses [82]. Therefore, stressed adipocytes can release large amounts of proinflammatory adipokines, such as leptin [83], and cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin (IL) 6, monocyte chemoattractant protein 1 (MCP-1), IL-1, and IL-8, which further promote inflammation [72,73]. All these changes create a low-grade inflammatory state in obese adipose tissue that is further amplified by cells of the immune system.

Macrophages are an abundant population of immune cells in adipose tissue. Some macrophages exist in lean adipose tissue, but their numbers increase dramatically during obesity. In obese adipose tissue, macrophages concentrate around apoptotic and dead
adipocytes, forming crown-like structures where defective adipocytes are eliminated by phagocytosis [23] (Figure 1b). The increase in macrophage numbers is due to a combination of recruitment, retention, and proliferation of these cells. Recruitment is mediated by myeloid C–C motif chemokine receptor-2 (CCR2), the receptor for MCP-1 [22], although other chemotactic agents also participate in macrophage recruitment to the adipose tissue [84]. Macrophage retention entails the direct contact of macrophages with adipocytes. This cell–cell contact is mediated by adhesion of integrin α4β1 on macrophages with vascular cell adhesion molecule-1 (VCAM-1) on adipocytes [85] (Figure 2). Macrophages are also capable of proliferating, particularly in the crown-like structures [24] where the inflammatory microenvironment provides Th2 cytokines, such as IL-4, IL-13, and granulocyte/monocyte colony-stimulating factor (GM-CSF), that stimulate macrophage growth [86].

Figure 2. Interaction of adipocytes and macrophages in obese adipose tissue. Macrophages enter in direct contact with adipocytes through adhesion of integrin α4β1 on macrophages with vascular cell adhesion molecule-1 (VCAM-1) on adipocytes. Free fatty acids (FFA) produced by lipolysis are released by adipocytes and bind to fetuin-A, which is then recognized by toll-like receptor 4 (TLR-4) on macrophages. This leads to the activation of proinflammatory signals like the nuclear factor kappa B (NF-κB) pathway that induces secretion of cytokines such as tumor necrosis factor alpha (TNF-α) by macrophages. The leptin released by adipocytes also induces macrophages to produce TNF-α. Further activation of macrophages by TNF-α creates a self-sustained inflammation in obese adipose tissue.

Accumulation of macrophages in obese adipose tissue goes together with the activation of these cells. Activation results in an increase in macrophages with the M1 (proinflammatory) phenotype and a decrease in M2 (anti-inflammatory) macrophages [22,87,88]. The
proinflammatory activation of macrophages in the adipose tissue involves many different extracellular factors, including lipids, adipokines, and cytokines [23,89,90]. Lipids, such as free fatty acids, deriving from enhanced lipolysis of dysfunctional adipocytes, are capable of activating macrophages via the interaction with toll-like receptor 4 (TLR-4) [90,91], resulting in the activation of proinflammatory signaling pathways, like the nuclear factor kappa B (NF-κB) and c-Jun N-terminal kinase (JNK) pathways [16]. Mechanistically, free fatty acids, however, do not directly engage TLR-4. Instead, they bind fetuin-A, which then binds to TLR-4, leading to the activation of proinflammatory signals [92,93] (Figure 2). Adipokines such as leptin, the hormone that inhibits hunger, are important activators of macrophages. Leptin induces macrophages to produce TNF-α, IL-6, MCP-1, and IL-1β [83,94]. Cytokines such as TNF-α, IL-6, and IL-1β are also important activators of macrophages [20,95]. Because all these proinflammatory factors are produced either by dysfunctional adipocytes [20] or by activated macrophages themselves, the activation of macrophages in obese adipose tissue becomes self-sustained. This is probably one of the reasons for the continuous low-grade inflammation of obesity [9,96].

So far, most studies on obesity have focused on the role of activation of macrophages and their accumulation in adipose tissues (reviewed in [89,95,97]). However, many other immune cells are also found in adipose tissues, including neutrophils, CD4 T cells, CD8 T cells, B cells, dendritic cells (DCs), and mast cells [17,98]. Recently, it has become evident that neutrophils are the first innate immune cells infiltrating obese adipose tissues and important regulators of the obesity-associated inflammation. We describe next the novel findings on the role of neutrophils in obesity.

5. Neutrophils in Obesity
5.1. Circulating Neutrophils Increase in Obesity

Neutrophils are the most abundant leukocytes in human blood, the primary effector cells of acute inflammation and the first responders to infections [99,100]. Neutrophils are typically considered to be the major leukocytes against infections due to their capacity to act as phagocytic cells [101], degranulate releasing lytic enzymes, perform an oxidative burst producing reactive oxygen species (ROS), and produce neutrophil extracellular traps (NETs) with antimicrobial potential [102,103]. Neutrophils are also considered as the main effector cells of acute inflammatory reactions since they are the first leukocytes to be recruited to inflammation sites where they are capable of producing large quantities of cytokines and chemokines including TNF-α, IL-1β, IL-8, and MCP-1 [104]. Consequently, neutrophils induce the second wave of immune cells, such as macrophages and lymphocytes, to inflammation sites [105,106].

Conspicuously, circulating neutrophils are increased in obesity [107–111], with a clear association between the level of neutrophil blood counts and the higher BMI [107,108,110]. Furthermore, overweight individuals with neutrophilia presented elevated serum C-reactive protein (CRP) concentrations and larger waist circumferences [107,108]. In addition, neutrophil counts were significantly higher in individuals with metabolic syndrome than in lean individuals [108]. In animal models, neutrophils have also been found to be elevated in blood vessels and infiltrating adipose tissue and the endothelium at atherosclerotic lesions [112]. Moreover, neutrophils in obese individuals present an activated phenotype as indicated by elevated plasma concentrations of myeloperoxidase (MPO) and neutrophil elastase (NE) [26,113], as well as an increased expression of CD66b, a marker of neutrophil degranulation [26,27]. Activation of neutrophils from obese individuals was also indicated by stimulation of the NF-κB signaling pathway [27] and by a higher ROS generation and enhanced release of proinflammatory cytokines [114].

Importantly, weight loss following gastric band surgery resulted in a decrease in neutrophil blood counts [115] and in proinflammatory activities of peripheral blood neutrophils [114]. These results suggest that the inflammatory condition of obesity also leads to the expansion of neutrophils [9,13,94]. In fact, elevated concentrations of acute-phase proteins have been reported in obese individuals [14,116]. As mentioned before, the adipose
tissue in obese individuals is capable of producing increased levels of mediators of inflammation like TNF-\(\alpha\), IL-1\(\beta\), IL-6, and IL-8 [117–122]. These inflammatory mediators increase bone marrow granulopoiesis [123–125], releasing neutrophils from the bone marrow to the peripheral circulation. Moreover, these inflammatory mediators induce de-margination of neutrophils from endothelial walls, resulting in neutrophilia [126]. In addition, the adipose tissue also produces leptin which has been shown to promote hematopoiesis [127–129]. Leptin can additionally stimulate the oxidative burst of neutrophils, induce chemotaxis, and inhibit apoptosis in these cells [127]. Together, these reports support the notion that, indeed, obese adipose tissue is responsible for promoting a systemic inflammation that results in the generation, increase in numbers, and activation of neutrophils. In consequence, these leukocytes are the first cells to infiltrate adipose tissues.

5.2. Neutrophil-to-Lymphocyte Ratio (NLR)

The clear connection between obesity and an elevated neutrophil blood count has motivated people to look for simple biomarkers of obesity and inflammation. The hematological parameter for systemic inflammation known as the neutrophil-to-lymphocyte ratio (NLR) is an easy biomarker of immune response to various infectious and noninfectious stimuli [130]. The NLR is commonly used in many medical areas as an indicator of dynamic changes of neutrophils and lymphocytes in blood during systemic inflammation. The NLR reflects the relationship between innate (neutrophils) and adaptive (lymphocytes) immune responses in various pathological conditions. Because the NLR correlates with CRP concentrations, it becomes a simple cost-effective biomarker for the detection of subclinical inflammation [131].

Accordingly, the NLR has been found to be significantly higher in obese individuals than in healthy lean individuals [132–135], with a positive correlation to the BMI [132,135–138]. As expected, the NLR is also associated with higher plasma CRP concentrations [111,132,139,140]. The same trend has been reported in mice fed with an obesogenic diet. The effect on the NLR seems to be due to changes in the gut microbiota, which affects blood leukocyte numbers [134]. The significant association between obesity and a high NLR (higher than 4) was a good predictor of increased breast cancer risk. Patients with a high NLR and a high BMI also had the worst disease-free survival [133,138]. More importantly, NLR values were found to correlate significantly with the degree of abdominal obesity [141,142]. Furthermore, in morbid obese patients, a high NLR was reported to be a powerful and independent predictor of type 2 diabetes mellitus (T2D) [143]. Hence, the NLR is a simple and accessible biomarker that provides information about the inflammatory state of obese individuals. Importantly, the NLR seems to be able to identify an ongoing systemic inflammation in overweight individuals that otherwise appear healthy [139,140]. Therefore, a higher NLR in overweight individuals may reflect the subclinical inflammation already present in this group of people.

5.3. Neutrophil Infiltration into Adipose Tissue

During obesity-induced inflammation in animal models, neutrophil numbers increase in the peripheral circulation. From there, neutrophils can infiltrate the adipose tissue [25] and blood vessel endothelium [112]. This suggested that neutrophils have an important role at the early stages of obesity by infiltrating the abdominal adipose tissue. Neutrophils are found in the adipose tissue of lean mice in very small numbers, approximately 1% of all immune cells in the adipose tissue [144]. Yet, in mice fed a high-fat diet, a 20-fold increase in adipose tissue neutrophils was observed as early as three days after initiation of the diet [25]. In contrast, macrophage infiltration can be detected after 7 days of a high-fat diet [145,146]. These results indicated that neutrophils are the first immune cells to be recruited into adipose tissues. Neutrophil infiltration was first described as transient because after an initial remarkable increase, the neutrophil numbers decreased [25]. However, the neutrophil numbers were higher for up to 12 weeks in the adipose tissue of the mice fed with a high-fat diet than in the adipose tissue of the mice fed a normal diet [25]. Moreover, it was later shown that early recruitment of neutrophils could be prolonged over 90 days with
a constant high-fat diet [19,147]. Hence, in the early phases of adipocyte dysfunction, the initial inflammatory response is characterized by neutrophil infiltration into adipose tissues. Neutrophils are recruited to the adipose tissue via the action of several chemotactic factors produced in the obese adipose tissue. Inflamed adipocytes produce larger amounts of IL-8, a potent neutrophil chemoattractant [19,117]. Once in the adipose tissue, neutrophils can recruit more blood neutrophils by releasing C–X–C motif chemokine ligand 2 (CXCL2), another important neutrophil chemoattractant [148] (Figure 3). Furthermore, lipids extracted from human adipocytes were shown to induce migration of neutrophils and macrophages, and also secretion of other cytokines [149]. In addition, free fatty acids derived from adipocyte lipolysis could also attract neutrophils and stimulate them to produce more IL-1β, which in turn activates other adipocytes and immune cells [30] (Figure 3). The exact molecular nature of the various lipid chemotactic factors is not yet known. Future studies will help elucidate these chemotactic factors and the mechanisms they use to recruit neutrophils into adipose tissues.

5.4. Neutrophil Activation and Inflammation

Once in the adipose tissue, neutrophils interact with adipocytes via the binding of integrin αMβ2 (Mac-1) on the neutrophil to intercellular adhesion molecule 1 (ICAM-1) on the adipocyte [25] (Figure 3). This interaction activates neutrophils and induces them to produce IL-1β and TNF-α, which further stimulate inflammation in the adipose tissue [98,150,151]. Neutrophils also secrete NE, which impairs the energy expenditure in the adipose tissue [152] and promotes insulin resistance by degrading insulin receptor substrate 1 (IRS-1) [147]. As the number of infiltrated neutrophils augments, the activity of NE is also increased in the adipose tissue of high-fat diet mice [19,147]. Importantly, genetic deletion of NE reduces macrophage infiltration into the adipose tissue of obese mice and reverts insulin resistance [147,153], indicating that NE is a key activator of macrophages (Figure 3). An important connection between IL-1β and the NLRP3 inflammasome was found in mice fed a high-fat diet. In the adipose tissue of these mice, the mRNA levels of both IL-1β and NLRP3 were positively correlated to body weight and adiposity [154]. Furthermore, when the mice were fed a calorie-restricted diet, the mRNA levels of both molecules were significantly decreased [154]. Together, these results suggest that the interaction of neutrophils with adipocytes induces IL-1β expression via the NF-κB pathway and that free fatty acids released after lipolysis of adipocytes also stimulate neutrophils to produce high levels of IL-1β via the inflammasome pathway [30] (Figure 3).

Therefore, the chronic low-grade inflammation of the adipose tissue leads to the activation of neutrophils [17]. Neutrophil activation was first inferred from the observation that serum NE concentrations [26] or plasma MPO concentrations [155] were increased in obese individuals. More recently, these observations were confirmed at the cellular level. In peripheral blood leukocytes, the NE and MPO mRNA levels were found to be positively correlated to the BMI and serum triglyceride concentrations [113]. Furthermore, bariatric surgery, which leads to weight loss in patients, partially reduced neutrophil activation [26]. Another evidence of neutrophil activation in adipose tissues is the fact that leptin can delay apoptosis of mature neutrophils. The antiapoptotic properties of leptin on neutrophils involve activation by the leptin receptor of the NF-κB and MEK1/2 MAPK signaling pathways [127,156] (Figure 3). Activation of neutrophils is also detected by the altered responses neutrophils of obese patients have to various stimuli. In general, these neutrophils display elevated ROS production and release of proinflammatory cytokines [114]. The elevated ROS production observed in neutrophils from obese people has also been reported in neutrophils from obese individuals of other species, including dogs [157] and horses [158].
Neutrophils are recruited to the adipose tissue via the action of several chemotactic factors produced in the obese adipose tissue. Inflamed adipocytes produce larger amounts of IL-8, a potent neutrophil chemoattractant [19,117]. Once in the adipose tissue, neutrophils can recruit more blood neutrophils by releasing C–X–C motif chemokine ligand 2 (CXCL2), another important neutrophil chemoattractant. Neutrophils directly interact with adipocytes via the binding of integrin α4β2 on the neutrophil to intercellular adhesion molecule 1 (ICAM-1) on the adipocyte. This interaction activates neutrophils and induces them to produce interleukin 1 beta (IL-1β) via the nuclear factor kappa B (NF-κB) and inflammasome (NLRP3) pathways. IL-1β is an important activator of macrophages. Neutrophils also produce tumor necrosis factor alpha (TNF-α), which further stimulates macrophages. Leptin, through its receptor, also activates the NF-κB pathway, resulting in the inhibition of neutrophil apoptosis. Free fatty acids (FFA) derived from adipocyte lipolysis can also attract neutrophils and stimulate them to produce more IL-1β. Neutrophils also produce elastase (NE) which impairs energy expenditure in the adipose tissue and directly activates macrophages. Granule protein cathelicidin (LL-37) can also activate the release of more proinflammatory cytokines from macrophages. Activated neutrophils can also recruit monocytes through the release of azurocidin, LL-37, cathepsin G, proteinase 3 (PR3), and human neutrophil peptides 1–3 (HNP1–3). In addition, lactoferrin, azurocidin, and HNP1–3 can induce polarization of macrophages towards the M1 proinflammatory phenotype.

Another important antimicrobial function of neutrophils is phagocytosis. There are only a handful of reports describing this function in neutrophils from obese individuals. In one study, neutrophils from obese noninsulin-dysregulated horses had a significantly increased ROS production, but no changes were observed in terms of phagocytosis [158]. In another very early study, the phagocytosis and killing of Candida albicans by neutrophils from healthy (control) and diabetic individuals were compared. Phagocytosis occurred at similar levels in neutrophils from diabetic and control individuals [159]. However, the killing of Candida by diabetic neutrophils was impaired [159]. In contrast, a recent report of neutrophils from mice on a high-fat diet showed that the phagocytosis of Klebsiella pneumoniae...
was reduced [160]. In most instances, independently of the level of phagocytosis reported, the killing capacity of neutrophils from obese individuals seems to be diminished. These findings agree with clinical observations consistently reporting that individuals with obesity are physiologically frail and have a higher risk of infections and mortality than normal-weight individuals [161,162]. Clearly, much work on neutrophil phagocytosis in obese individuals is needed to fully understand why the activated state of neutrophils from obese individuals does not translate into a more effective antimicrobial function.

Because activated neutrophils have the ability to increase their secretion of cytokines and chemokines, they are also described as the prime effectors of inflammatory responses [98]. As such, they are able to induce the recruitment and activation of the second wave of immune cells, including macrophages, dendritic cells, and lymphocytes [146,163]. Once at the inflamed adipose tissue, neutrophils recruit monocytes through the release of LL-37 (cathelicidin/CRAMP), azurocidin (heparin-binding protein), cathepsin G, proteinase 3 (PR3), and human neutrophil peptides 1–3 (HNP1–3) [164,165] (Figure 3). Neutrophils can then induce monocyte differentiation and macrophage polarization and activation. Lactoferrin [166], azurocidin [167], and HNP1–3 [168] can induce polarization of macrophages towards the M1 proinflammatory phenotype (Figure 3). In addition, LL-37 induces M1 macrophage polarization and release of proinflammatory cytokines [169] (Figure 3). Similarly, alarmin S100A9 also induces the release of proinflammatory cytokines from synovial macrophages [170]. Thus, neutrophil proteins contribute to inflammation intensification by promoting macrophage activation and release of proinflammatory cytokines (Figure 3).

5.5. Neutrophil Extracellular Traps (NETs)

As mentioned, another way neutrophils control infections is the production of neutrophil extracellular traps (NETs), which are fibers of decondensed chromatin (DNA) decorated with histones and antimicrobial proteins from neutrophil granules. NETs are formed and released by a dynamic cell death program known as NETosis. In addition to infections, NETosis can take place during noninfectious sterile inflammation, where neutrophils help repair damaged tissues. However, during persistent inflammation, NETs can aggravate the tissue damage [171,172]. Because obesity is associated with chronic systemic inflammation, it is possible that NETosis is activated, and NETs may contribute to some of the medical complications associated with obesity.

The role of NETs in obesity is not clear since there are conflicting reports. For example, in a diet-induced obesity mouse model, endothelial dysfunction was observed. In these mice, plasma concentrations of LL-37 were increased in mesenteric arterial walls. LL-37 was used as a marker for NETs [173]. Disruption of NETs with DNase restored the endothelium function, suggesting that NETs are increased in obesity and are responsible for endothelial dysfunction [173]. Similarly, in obese persons, plasma concentrations of MPO–DNA complexes (assessed by ELISA) were higher than in lean persons. Moreover, NETs concentrations correlated with the BMI [174]. In addition, recent bioinformatics studies found a strong relationship between obesity, inflammatory markers, such as TNF-α, IL-6, IL-8, heat shock protein 90 (HSP90), and NETs formation [175,176]. Moreover, it was also found that exercise reduces NETs [175]. Together, these reports suggest that obesity-induced inflammation is associated with elevated NETs formation. However, in other studies, an opposite relationship was reported. Using purified neutrophils from obese individuals and in vitro testing, it was found that although neutrophils displayed an activated phenotype (elevated ROS production), they exhibited lower NETs formation than neutrophils from lean individuals [114]. Similarly, using intravital microscopy in mice kept on a high-fat diet, it was revealed that neutrophils produce fewer NETs in liver vasculature than neutrophils from lean mice (kept on a normal diet) [177].

Extending these observations to neutrophils from diabetic individuals, it is also found that the role of NETs in this obesity-related condition is, again, not clear. Detecting NE–DNA complexes as an indicator of NETs, it was reported that recently diagnosed T2D patients
had higher plasma levels of NETs than healthy (control) individuals [178]. Furthermore, measuring NE and histone/DNA complexes in serum, it was concluded that NETs were increased in patients with diabetic retinopathy [179]. In another report, neutrophils from diabetic patients with proliferating retinopathy also presented increased NETs production, particularly when exposed to high levels of glucose [180]. These results are similar to those reported in a previous study, where diabetic patients had elevated NETs components in serum, and neutrophils presented enhanced NETosis in case of high levels (25 mM) of glucose [181]. Together, these reports suggest that diabetic conditions, particularly high glucose, lead to enhanced NETosis. However, other reports indicate that high glucose concentrations decrease the formation of NETs [182,183].

Nevertheless, the role for NETs in diabetic wound healing seems more clearly established [184–186]. Diabetic patients frequently have foot lesions that do not heal. These individuals are referred to as diabetic foot patients [187]. In a model of wound healing, skin wounds were inflicted on mice. Healing of these lesions was longer in diabetic mice than in normoglycemic (control) mice [184]. Furthermore, when the wounds were treated with DNase 1 to degrade NETs, wound healing was improved both in the diabetic mice and the control mice [184]. In addition, the wounds of diabetic animals presented larger amounts of citrullinated histone H3 (H3Cit), a marker for NETosis. In contrast, no H3Cit was observed in the wounds from the \( Padi4^{-/-} \) mice (deficient in enzyme peptidylarginine deiminase 4 (PAD4) that causes histone citrullination), despite many neutrophils present. More importantly, the wounds of the \( Padi4^{-/-} \) mice healed very fast [184]. In another study, neutrophils were stimulated with PMA to induce NETosis, and NETs formation was abolished by treatment with hydrogen sulfide (H\(_2\)S) [186]. Furthermore, diabetic mice with wounds were treated intraperitoneally with H\(_2\)S. The wounds in these mice had decreased NETs markers (NE, MPO, H3Cit, and PAD4) and healed better than the wounds in the control mice [185]. In a more recent study, intravital microscopy detected enrichment of NETs components in the bed of excisional wounds, and inhibition of PAD4 with BB-Cl-amidine improved wound healing in diabetic mice [186]. Together, these results suggested that diabetes slows down wound healing by activating NETosis. Mechanistically, NETs slow down wound healing in diabetic animals by triggering NLRP3 inflammasome activation via the TLR-4/TLR-9/NF-\( \kappa \)B signaling pathway in macrophages. As a result, macrophages release IL-1\( \beta \) and prolong the inflammatory response in the diabetic wound [188,189].

At the present time, it is not possible to decide with confidence whether NETs formation is enhanced or reduced in obesity. The discrepancy among the various studies may be related to the different methodological approaches used to evaluate NETs. In some studies, indirect assessments were made by detecting some NETs components in plasma or serum. In other studies, NETs formation was evaluated directly in vitro with purified neutrophils. Yet, in other studies, intravital microscopy was used to detect NETs. Methods detecting NETs components do not necessarily confirm that NETosis took place. Elevated circulating DNA or neutrophil granule proteins may be caused by several other reasons besides NETosis. In vitro assays with purified neutrophils are more reliable to detect NETs. In either case, authors should be aware of the limitations of the methodology used and take them into consideration when interpreting the experimental results. Another possible reason for the discrepancy among the reported results is that neutrophil function may be affected by the metabolic and inflammatory states of the individual. Earlier, it was shown that NETs formation is dependent on glucose. Upon PMA stimulation, neutrophils increased glucose uptake and their glycolysis rate (as measured with a Seahorse analyzer). In the absence of glucose, PMA induced neutrophils to decondense chromatin, but they did not release NETs. However, if glucose was added at this time, NETs release took place within minutes [190]. Based on these data, the authors suggested that NETs formation could be metabolically divided into two phases: the first, independent from exogenous glucose (chromatin decondensation), and the second (NETs release), dependent on exogenous glucose and glycolysis [190]. More recently, it was reported that neutrophils from mice fed a normal diet used glycolysis for NETs release in both physiological and inflammatory
(sepsis) conditions. However, neutrophils from mice fed a high-fat diet could not release NETs after a secondary ex vivo activation despite the high glycolytic potential and the flexibility to oxidize fatty acids [191]. Thus, the metabolic and inflammation states of the individual can influence the neutrophil function. In the future, extensive well-controlled studies will be required to elucidate the role of NETs in obesity.

6. Neutrophils in Type 1 Diabetes (T1D)

Diabetes mellitus, commonly referred to only as diabetes, is a group of metabolic disorders characterized by hyperglycemia over long periods of time. Diabetes is due to either lack of insulin secretion from the β cells in the pancreas or insulin resistance, a condition in which cells of the body do not respond properly to insulin [192]. There are two main types of diabetes: type 1 (insulin deficiency) and type 2 (insulin resistance) [193]. Both diabetes types are associated with serious clinical complications such as cardiovascular disorders, heart failure, atherosclerosis, diabetic neuropathy, diabetic retinopathy, and diabetic kidney disease [194–196].

Type 1 diabetes mellitus (T1D) is considered a T cell-mediated autoimmune disease, in which autoreactive T lymphocytes destroy the insulin-producing β cells in the pancreatic islets [197]. Much progress has been made in understanding T1D thanks to the nonobese diabetic (NOD) mouse animal model [198]. Similar to human T1D, NOD mice exhibit an autoimmune response towards β cells, resulting in the dysfunction and destruction of these cells. However, a limitation of this model is that in NOD mice, the initial antigen is insulin [199], while in humans, anti-islet autoantibodies are the most frequently detected autoantibodies [200]. In a study of Japanese T1D patients, it was reported that the main antigens recognized by autoantibodies were glutamic acid decarboxylase (GAD), insulinoma-associated antigen-2 (IA-2), zinc transporter 8 (ZnT8), and insulin [201].

Pioneering work with NOD mice demonstrated that physiological β cell death induced the recruitment and activation of B-1a cells and plasmacytoid dendritic cells to the pancreas [202]. These events represent the initial immunological steps for developing T1D. Importantly, in this first study, a significant early infiltration of neutrophils to the pancreas was also reported [202]. At the same time, it was found that circulating neutrophil numbers were reduced in T1D patients and that neutrophils were present in the pancreas of patients with T1D but not in patients with T2D or in nondiabetic controls [203]. A reduction in circulating neutrophils has been confirmed in other studies and it is considered a hallmark of T1D [204–208]. Moreover, this reduction of neutrophils correlates with lower serum levels of NE and PR3 [209] and with faster disease progression [206,210]. The reduction of circulating neutrophils is due mainly to neutrophil infiltration into the pancreatic tissue [203,206]. In neonatal NOD mice, neutrophil infiltration [211,212] and NE concentrations in the pancreas [211,213] are already higher than in control mice as early as at two weeks of age. Macrophages and β cells produce chemokines CXCL1 and CXCL2, which in turn recruit CXCR2-expressing neutrophils to the pancreas [212] (Figure 4). Thus, neutrophils emerge as important cells participating in the early stages of T1D development. This is not too surprising, since recently neutrophils have been recognized as key components of both the innate and adaptive immune systems [105] and as important participants in the immunization and the effector phases of autoimmune diseases [214].

As seen in several autoimmune diseases, NETosis might contribute to promoting both inflammation and tissue damage. In the case of T1D, NETs components have been detected in circulation. However, there are contradictory reports. Increased NETs components (NE and PR3 proteins) were reported in the serum of patients with T1D [206,215]. Yet, in a previous report, reduced circulating levels of NETs components were found to correlate with the reduced number of circulating neutrophils [209]. However, NETosis within the pancreas clearly contributes to disease progression [216]. Neutrophil infiltration into pancreatic islets of NOD mice correlates with higher levels of citrullination [217]. Thus, by inhibiting NE with sivelestat or elafin [211] or PAD4 with BB-Cl-amidine [217], the development of diabetes was prevented in NOD mice. Similarly, by degrading NETs with
staphylococcal nuclease (SNase) (delivered to NOD mice by oral administration of modified *Lactococcus lactis*), pancreatic inflammation was reduced, β cell numbers increased, and glucose tolerance was improved [218]. Moreover, neutrophils isolated from T1D patients had an increased expression of PAD4 and showed enhanced NETosis after stimulation [184]. In vitro, NETs isolated from T1D pediatric patients induced monocyte-derived dendritic cell activation, leading to the production of interferon gamma (IFN-γ) by T cells [219] (Figure 4). Although NETs do not seem to directly induce the production of autoantibodies, they favor β cell damage resulting in exposure of the antigens recognized by anti-islet autoantibodies.

Neutrophils can also directly activate B cells via secreted cytokines such as BAFF (B cell-activating factor of the TNF family). BAFF, acting through its receptor [220], is one of the main prosurvival factors for B cells as well as for antibody-producing plasma cells [221] (Figure 4). Hence, neutrophils and NET components have an evident contribution to the development of T1D. These findings may open new opportunities for innovative therapeutic approaches in the future.

In addition, several neutrophil functions, including phagocytosis, degranulation, and production of ROS, have been reported to be reduced in patients with T1D [159,222,223]. All these defects are thought to be caused by hyperglycemia [224,225]. However, it was recently found that in vitro neutrophil migration was impaired in neutrophils from T1D but not from T2D patients [207]. This functional defect was associated with the expression of L-selectin (CD62L) but not with high glucose concentrations [207]. Thus, it may be possible
that certain neutrophil defects are specific features of T1D and not a general glucose-dependent defect. Future studies should look more carefully into neutrophil functions at different stages of diabetes.

7. Neutrophils in Type 2 Diabetes (T2D)

Type 2 diabetes mellitus (T2D) is a chronic disease characterized by an elevated concentration of glucose in blood as a result of limited insulin secretion and/or insulin resistance. As a consequence, in T2D, the metabolism of carbohydrates, lipids, and proteins is dysregulated [226].

T2D is associated with obesity-induced chronic systemic inflammation [13,15]. As described above, neutrophil infiltration into adipose tissues contributes to the development of insulin resistance. In mice fed a high-fat diet, neutrophils in the adipose tissue release NE which degrades IRS1, resulting in impaired insulin signaling [147] (Figure 5).

Therefore, genetically NE-deficient mice showed reduced adipose tissue inflammation and increased glucose tolerance, including better insulin sensitivity [147,152]. Furthermore, activated neutrophils from diabetic patients released more IL-1, IL-6, IL-8, and TNF-α than neutrophils from healthy individuals [227], leading to the increased level of circulating inflammatory cytokines. These elevated cytokines may then impact multiple organs in the body. One cytokine that has been repeatedly implicated in T2D is TNF-α [119,228]. Neutrophils from T2D patients secrete higher amounts of IL-6 and TNF-α in response to lipopolysaccharide (LPS) stimulation, resulting in insulin resistance, which then increases the blood glucose concentration [227]. Similarly, in the serum of obese patients with cardiovascular disease, larger TNF-α concentrations have been reported [229].

TNF-α has also been implicated in other mechanisms that contribute to the development of T2D, for example, altered function of endothelial cells [230,231]. Changes in the expression of adhesion molecules by vascular endothelial cells are observed in patients with T2D, and these changes seem to occur even before the onset of T2D [232]. Altered adhesion function of endothelial cells has also been associated with the progression of atherosclerosis [233]. TNF-α seems to be responsible for these alterations by inducing an increased low-density lipoprotein uptake in vascular endothelial cells [234] (Figure 5). This process can then promote atherosclerosis and extend inflammation [234]. Consequently, genetically TNF-α-deficient mice show less endothelial cell dysfunction in diabetes animal models [231,235]. In addition, TNF-α has been linked to β cell dysfunction and insulin resistance. TNF-α and IL-1 induced β cell dedifferentiation in cultured human and mouse pancreatic islets by downregulating transcription factor Fox01, which regulates β cell proliferation [236,237] (Figure 5).

The elevated levels of circulating inflammatory cytokines found in diabetic patients and animals also have important effects on neutrophil function. Neutrophils of diabetic individuals display lower phagocytic activity [159], lower production of ROS [225], and lower chemotactic capacity [238] than neutrophils from healthy control individuals. Some of these functions (migration and bacteria killing) also seem to be compromised in hyperglycemia, and can be induced in vitro upon exposure of neutrophils to serum from diabetic patients [182]. Finally, recent experiments showed that neutrophils can release microvesicles, which are involved in cell–cell communication. The neutrophil microvesicles concentration increased in the mice fed a high-fat diet. These microvesicles also accumulate in certain regions of arteries and promote vascular inflammation and atherosclerosis. In vitro, neutrophil microvesicles promoted inflammatory gene expression by endothelial cells [239]. Together, these reports suggest that neutrophils actively contribute to maintaining systemic inflammation and originating some pathological consequences found in T2D.
Figure 5. Neutrophils in obesity-related complications. Neutrophils in obese adipose tissue release large amounts of interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor alpha (TNF-α). These cytokines have important systemic effects leading to obesity-related complications. IL-8 recruits more neutrophils into the adipose tissue, creating an amplification cycle. Neutrophil elastase (NE) and IL-6 contribute to the development of insulin resistance by impairing insulin signaling. IL-1β is an important activator of macrophages in multiple parts of the body. Furthermore, IL-1β, together with TNF-α in pancreatic islets, induces β cell dedifferentiation by downregulating transcription factor Fox01, which regulates β cell proliferation. Together, these events may result in type 2 diabetes mellitus. In addition, TNF-α can alter the adhesion function of endothelial cells by inducing increased low-density lipoprotein (LDL) uptake. These changes have been associated with the progression of atherosclerosis.

8. Concluding Ideas

Obesity is a growing health problem of pandemic proportions. Obese people develop many pathological conditions, collectively referred to as obesity-related complications, including, among others, diabetes mellitus, cardiovascular diseases, and cancer. These conditions are thought to be initiated or worsened by the mild, chronic, systemic inflammation characteristic of obesity. This inflammatory condition is initiated by dysfunctional adipocytes, but later it is perpetuated by cells of the innate immune system, primarily neutrophils and macrophages. In recent years, it has become apparent that neutrophils are the first immune cells infiltrating the obese adipose tissue. Neutrophils then get activated and release multiple inflammatory factors that recruit other immune cells and further promote inflammation. The cellular and molecular mechanisms used by neutrophils to orchestrate
this scenario are only partially described. Consequently, several roles neutrophils play in obesity remain unidentified. Some of the more pressing issues that should be addressed in future research are mentioned next.

An evident characteristic of obesity is that circulating neutrophils are elevated. This increase in neutrophil blood counts seems to be associated with the severity of obesity, i.e., with the BMI and with inflammation markers such as plasma CRP. However, almost nothing is known about the relationship between neutrophil numbers and the inflammation state of persons with different grades of obesity. Using the inflammation biomarker NLR may be a way to detect an ongoing subclinical inflammation in individuals who otherwise appear healthy. This may be particularly relevant in overweight individuals who may be more susceptible to becoming obese. Although the NLR is firmly established, its use in routine clinical practice remains very limited.

We described that it is now clear neutrophils are recruited to obese adipose tissue. However, neutrophil infiltration is not the same in the adipose tissue from different individuals. What are the signals that attract neutrophils to this tissue under different conditions? The molecular nature of lipid chemotactic factors is not yet known. Future studies will help elucidate these chemotactic factors and the mechanisms they use to recruit neutrophils into adipose tissues. In general, it seems that neutrophils in obese individuals have an activated phenotype, revealed by an elevated ROS production. However, almost nothing is known about other neutrophil functions, such as chemotaxis, phagocytosis, and NETs formation. This is a very relevant issue because obese individuals appear to have a higher risk of infections and mortality than normal-weight individuals. How is it possible that “activated” neutrophils in obese people fail to control infections? Clearly, future research should concentrate on neutrophil phagocytosis in obese individuals to fully understand why neutrophils from obese individuals do not show an effective antimicrobial activity. In these future studies, it will also be important to evaluate neutrophil phagocytosis in cells from people with different grades of obesity; and to separate obesity studies from diabetes studies. Although diabetes is a complication of obesity, neutrophils from two individuals with similar obesity, one with diabetes and another without it, will most likely behave differently.

Another important topic that nowadays persists as very confusing is the role of NETs in obesity, particularly of how NETs may perpetuate inflammation and how NETs influence the antimicrobial function. As described above, presently, it is not clear whether NETs formation is enhanced or reduced in obesity. The discrepancy among the various studies seems to be related to the different methodological approaches used to evaluate NETs. Methods detecting NETs components do not necessarily confirm NETosis took place. Hence, it is imperative to validate the presence of actual NETs not only by detecting the “NETs markers” (NE, MPO, H3Cit), but also by demonstrating that actual chromatin fibers decorated with these molecules are present. This is particularly relevant when trying to detect NETs in circulating blood. In vitro assays with purified neutrophils are more reliable for detecting NETs. However, even in this case, proper confirmation that NETs are present is required. Therefore, future studies should use more than just one method to detect NETs formation. Presence of NETs can alter various aspects of cell behavior and thus generate different pathological outcomes. It is of great importance to discover what NETs do in different obesity conditions.

Neutrophil functions may be affected by the metabolic state of the individual. Reports on how hyperglycemia modify neutrophil responses are contradictory. Future studies on neutrophil responses should take into consideration the metabolic condition of the person donating the cells, and also tests in different laboratories should use similar conditions to assay neutrophils in vitro. For example, including similar glucose concentrations in all experiments.

Neutrophils are very flexible cells and, clearly, they can display multiple phenotypes [240]. Although not discussed in this review, a subpopulation of neutrophils, the so-called low-density neutrophils (LDNs), have been reported in many pathological conditions. No information on the presence or functionality of this subpopulation of neutrophils exists for obese
individuals. The possible role of LDNs in obesity is also an interesting line of future research. Similarly, the influence of the microbiota on neutrophil functions is another topic not much studied [134,241]. Because microbiota composition is changed during obesity, it will be of much interest to explore how the microbiota affects neutrophil functions during obesity.

**Author Contributions:** Conceptualization, E.U.-Q. and C.R.; data curation, C.R.; writing—original draft preparation, C.R.; writing—review and editing, E.U.-Q. and C.R.; visualization, E.U.-Q.; funding—acquisition, E.U.-Q. and C.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by grant IN202520 (to C.R.) and grant IN222120 (to E.U.-Q) from Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

**Data Availability Statement:** This study did not report any data.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Engin, A. The definition and prevalence of obesity and metabolic syndrome. *Adv. Exp. Med. Biol.* 2017, 960, 1–17. [CrossRef]
2. González-Muniesa, P.; Martínez-González, M.A.; Hu, F.B.; Després, J.P.; Matsuzawa, Y.; Loos, R.J.F.; Moreno, L.A.; Bray, G.A.; Martínez, J.A. Obesity. *Nat. Rev. Dis. Primers* 2017, 3, 17034. [CrossRef]
3. Williams, E.P.; Mesidor, M.; Winters, K.; Dubbert, P.M.; Wyatt, S.B. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. *Curr. Obes. Rep.* 2015, 4, 363–370. [CrossRef]
4. McAllister, E.J.; Dhurandhar, N.V.; Keith, S.W.; Aronne, L.J.; Barger, J.; Baskin, M.; Benca, R.M.; Biggio, J.; Boggiano, M.M.; Eisenmann, J.C.; et al. Ten putative contributors to the obesity epidemic. *Crit. Rev. Food Sci. Nutr.* 2009, 49, 868–913. [CrossRef]
5. Ng, M.; Fleming, T.; Robinson, M.; Moreno, L.A.; Bray, G.A.; Ezzati, M.; Calvo, Y.; Lobstein, T.; Le Maitre, C.R.; Baur, L.; et al. Global, national, and regional prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014, 384, 766–778. [CrossRef]
6. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19·2 million participants. *Lancet* 2016, 397, 1998. [CrossRef]
7. Blüher, M. Obesity: Global epidemiology and pathogenesis. *Nat. Rev. Endocrinol.* 2019, 15, 288–298. [CrossRef]
8. Chooi, Y.C.; Ding, C.; Magkos, F. The epidemiology of obesity. *Metab. Clin. Exp.* 2019, 92, 6–10. [CrossRef]
9. Artemniak-Wojtowicz, D.; Kucharska, A.M.; Pyržak, B. Obesity and chronic inflammation crosslinking. *Cent.-Eur. J. Immunol.* 2020, 45, 461–468. [CrossRef]
10. Zatterale, F.; Longo, M.; Naderi, J.; Raciti, G.A.; Desiderio, A.; Miele, C.; Beguinot, F. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. *Front. Physiol.* 2020, 10, 1607. [CrossRef]
11. Zhou, Y.; Chi, J.; Lv, W.; Wang, Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). *Diabetes/Metab. Res. Rev.* 2021, 37, e3377. [CrossRef]
12. Ghaben, A.L.; Scherer, P.E. Adipogenesis and metabolic health. *Nat. Rev. Mol. Cell Biol.* 2019, 20, 242–258. [CrossRef]
13. Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. *Annu. Rev. Immunol.* 2011, 29, 415–445. [CrossRef]
14. Illán-Gómez, F.; González-Ortega, M.; Orea-Soler, I.; Alcaraz-Tafalla, M.S.; Aragón-Alonso, A.; Pascual-Díaz, M.; Pérez-Paredes, M.; Lozano-Almela, M.L. Obesity and inflammation: Change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. *Obes. Surg.* 2012, 22, 950–955. [CrossRef]
15. Shoelsorn, S.E.; Herrero, L.; Naaz, A. Obesity, inflammation, and insulin resistance. *Gastroenterology* 2007, 132, 2169–2180. [CrossRef]
16. Chung, K.J.; Nati, M.; Chavakis, T.; Chatzigeorgiou, A. Innate immune cells in the adipose tissue. *Rev. Endocr. Metab. Disord.* 2018, 19, 283–292. [CrossRef]
17. Michailidou, Z.; Gomez-Salazar, M.; Alexaki, V.I. Innate immune cells in the adipose tissue in health and metabolic disease. *J. Innate Immun.* 2022, 14, 4–30. [CrossRef]
18. Kawai, T.; Autieri, M.V.; Scalia, R. Adipose tissue inflammation and metabolic dysfunction in obesity. *Am. J. Physiol. Cell Physiol.* 2021, 320, C375–C391. [CrossRef]
19. Blaszczak, A.M.; Jalilvand, A.; Hsueh, W.A. Adipocytes, innate immunity and obesity: A mini-review. *Front. Immunol.* 2021, 12, 650768. [CrossRef]
20. Maurizi, G.; Della Guardia, L.; Maurizi, A.; Poloni, A. Adipocytes properties and crosstalk with immune system in obesity-related inflammation. *J. Cell. Physiol.* 2018, 233, 88–97. [CrossRef]
21. Harman-Boehm, I.; Blüher, M.; Redel, H.; Sion-Vardy, N.; Ovadia, S.; Avinoach, E.; Shai, I.; Klöting, N.; Stumvoll, M.; Bashan, N.; et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: Effect of regional adiposity and the comorbidities of obesity. *J. Clin. Endocrinol. Metab.* 2007, 92, 2240–2247. [CrossRef]
22. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W., Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Investig.* **2003**, *112*, 1796–1808. [CrossRef]

23. Cinti, S.; Mitchell, G.; Barbatelli, G.; Murano, I.; Ceresi, E.; Faloia, E.; Wang, S.; Fortier, M.; Greenberg, A.S.; Obin, M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J. Lipid Res.* **2005**, *46*, 2347–2355. [CrossRef]

24. Haase, J.; Weyer, U.; Immig, K.; Klötting, N.; Blüher, M.; Eilers, J.; Bechmann, I.; Gericke, M. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation. *Diabetologia* **2014**, *57*, 562–571. [CrossRef]

25. Elgazzar-Carmon, V.; Rudich, A.; Hadad, N.; Levy, R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. *J. Lipid Res.* **2008**, *49*, 1894–1903. [CrossRef]

26. Nijhuis, J.; Rensen, S.S.; Slatts, Y.; van Dielen, E.M.; Buurman, W.A.; Greve, J.W. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. *Obesity* **2009**, *17*, 2014–2018. [CrossRef]

27. Shah, T.J.; Leik, C.E.; Walsh, S.W. Neutrophil infiltration and systemic vascular inflammation in obese women. *Reprod. Sci.* **2010**, *17*, 116–124. [CrossRef]

28. Xu, X.; Su, S.; Wang, X.; Barnes, V.; De Miguel, C.; Ownby, D.; Pollock, J.; Snieder, H.; Chen, W.; Wang, X. Obesity is associated with more activated neutrophils in African American male youth. *Int. J. Obes.* **2015**, *39*, 26–32. [CrossRef]

29. Herrero-Cervera, A.; Soehnlein, O.; Kenne, E. Neutrophils in chronic inflammatory diseases. *Cell. Mol. Immunol.* **2022**, *19*, 177–191. [CrossRef]

30. Watanabe, Y.; Nagai, Y.; Honda, H.; Okamoto, N.; Yanagibashi, T.; Ogasawara, M.; Yamamoto, S.; Imamura, R.; Takasaki, I.; Hara, H.; et al. Bidirectional crosstalk between neutrophils and adipocytes promotes adipose tissue inflammation. *FASEB J.* **2019**, *33*, 11821–11835. [CrossRef]

31. World Health Organization. Obesity and Overweight. Available online: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 10 January 2022).

32. Cerhan, J.R.; Moore, S.C.; Jacobs, E.J.; Kitahara, C.M.; Rosenberg, P.S.; Adami, H.O.; Ebbert, J.O.; English, D.R.; Gapstur, S.M.; Gapstur, S.M.; et al. Metagenomic analysis of the human distal gut microbiome. *Science* **2020**, *372*, 84–101. [CrossRef] [PubMed]

33. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; et al. The definition, diagnosis, and classification of diabetes mellitus and its complications. *Diabetes* **2009**, *58*, 26–31. [CrossRef] [PubMed]

34. Favieri, F.; Forte, G.; Casagrande, M. The executive functions in overweight and obesity: A systematic review of neuropsychological cross-sectional and longitudinal studies. *Front. Psychol.* **2019**, *10*, 2126. [CrossRef]

35. Jauch-Chara, K.; Oltmanns, K.M. Obesity–A neuropsychological disease? Systematic review and neuropsychological model. *Prog. Neurobiol.* **2014**, *114*, 84–101. [CrossRef]

36. Tilg, H.; Zmora, N.; Adolph, T.E.; Elinav, E. The intestinal microbiota fuelling metabolic inflammation. *Nat. Rev. Immunol.* **2020**, *20*, 40–54. [CrossRef]

37. Gill, S.R.; Pop, M.; Deboy, R.T.; Eckburg, P.B.; Turnbaugh, P.J.; Samuel, B.S.; Gordon, J.I.; Relman, D.A.; Fraser-Liggett, C.M.; Nelson, K.E. Metagenomic analysis of the human distal gut microbiome. *Science* **2006**, *312*, 1355–1359. [CrossRef]

38. Ursell, L.K.; Haiser, H.J.; Van Treuren, W.; Garg, N.; Reddivari, L.; Vanamala, J.; Dorrestein, P.C.; Turnbaugh, P.J.; Knight, R. The intestinal metabolome: An intersection between microbiota and host. *Gastroenterology* **2014**, *146*, 1470–1476. [CrossRef]

39. Cani, P.D.; Van Hul, M. Gut microbiota and obesity: Causally linked? *Expert Rev. Gastroenterol. Hepatol.* **2020**, *14*, 401–403. [CrossRef]

40. Crovesy, L.; Masterson, D.; Rosado, E.L. Profile of the gut microbiota of adults with obesity: A systematic review. *Eur. J. Clin. Nutr.* **2020**, *74*, 1251–1262. [CrossRef]

41. Cuevas-Sierra, A.; Ramos-Lopez, O.; Riezu-Boj, J.I.; Milagro, F.I.; Martinez, J.A. Diet, gut microbiota, and obesity: Links with host genetics and epigenetics and potential applications. *Adv. Nutr.* **2019**, *10*, S17–S30. [CrossRef] [PubMed]

42. Cunningham, A.L.; Stephens, J.W.; Harris, D.A. A review on gut microbiota: A central factor in the pathophysiology of obesity. *Lipids Health Dis.* **2021**, *20*, 65. [CrossRef] [PubMed]

43. Lee, C.J.; Sears, C.L.; Maruthur, N. Gut microbiome and its role in obesity and insulin resistance. *Ann. N. Y. Acad. Sci.* **2020**, *1461*, 37–52. [CrossRef] [PubMed]

44. Bäckhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenovych, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 15718–15723. [CrossRef] [PubMed]

45. Bäckhed, F.; Manchester, J.K.; Semenovych, C.F.; Gordon, J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 979–984. [CrossRef]

46. Ley, R.E.; Bäckhed, F.; Turnbaugh, P.; Lozupone, C.A.; Knight, R.D.; Gordon, J.I. Obesity alters gut microbial ecology. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 11070–11075. [CrossRef]

47. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* **2006**, *444*, 1027–1031. [CrossRef]

48. Cani, P.D. Human gut microbiome: Hopes, threats and promises. *Gut* **2018**, *67*, 1716–1725. [CrossRef]
Cells 2022, 11, 1883

49. Liu, B.N.; Liu, X.T.; Liang, Z.H.; Wang, J.H. Gut microbiota in obesity. *World J. Gastroenterol.* 2021, 27, 3837–3850. [CrossRef]

50. Wei, Y.X.; Zheng, K.Y.; Wang, Y.G. Gut microbiota-derived metabolites as key mucosal barrier modulators in obesity. *World J. Gastroenterol.* 2021, 27, 5555–5565. [CrossRef]

51. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.; Chabo, C.; et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 2007, 56, 1761–1772. [CrossRef]

52. Cani, P.D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A.M.; Delzenne, N.M.; Bercelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 2008, 57, 1470–1481. [CrossRef] [PubMed]

53. Amar, J.; Bercelin, R.; Ruidavets, J.B.; Cani, P.D.; Fauvel, J.; Alessi, M.C.; Chamontin, B.; Ferrières, J. Energy intake is associated with endotoxemia in apparently healthy men. *Am. J. Clin. Nutr.* 2008, 87, 1219–1223. [CrossRef] [PubMed]

54. Boulange, C.L.; Neves, A.L.; Chiloux, J.; Nicholson, J.K.; Dumas, M.E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Med.* 2016, 8, 42. [CrossRef]

55. Janssen, A.W.; Kersten, S. Potential mediators linking gut bacteria to metabolic health: A critical view. *J. Physiol.* 2017, 595, 477–487. [CrossRef] [PubMed]

56. Maslowski, K.M.; Vieira, A.T.; Ng, A.; Kranich, J.; Sierro, F.; Yu, D.; Schilter, H.C.; Mackay, F.; Artis, D.; et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 2009, 461, 1282–1286. [CrossRef]

57. Lin, H.V.; Frassetto, A.; Kowalik, E.J., Jr.; Nawrocki, A.R.; Lu, M.M.; Kosinski, J.R.; Hubert, J.A.; Szeto, D.; Yao, X.; Forrest, G.; et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS ONE* 2012, 7, e35240. [CrossRef]

58. Murphy, K.G.; Bloom, S.R. Gut hormones and the regulation of energy homeostasis. *Nature* 2006, 444, 854–859. [CrossRef]

59. Kimura, I.; Ichimura, A.; Ohue-Kitano, R.; Igarashi, M. Free fatty acid receptors in health and disease. *Physiol. Rev.* 2020, 100, 171–210. [CrossRef]

60. Overby, H.B.; Ferguson, J.F. Gut microbiota-derived short-chain fatty acids facilitate microbiota-host cross talk and modulate obesity and hypertension. *Curr. Hypertens. Rep.* 2021, 23, 8. [CrossRef]

61. Vinolo, M.A.; Rodrigues, H.G.; Nachbar, R.T.; Curi, R. Regulation of inflammation by short chain fatty acids. *Nutrients* 2011, 3, 858–876. [CrossRef]

62. Aoyama, M.; Kotani, J.; Usami, M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. *Nutrition* 2010, 26, 653–661. [CrossRef] [PubMed]

63. da Silva, T.F.; Casarotti, S.N.; de Oliveira, G.L.V.; Penna, A.L.B. The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hosts. *Crit. Rev. Food Sci. Nutr.* 2021, 61, 337–355. [CrossRef] [PubMed]

64. Green, M.; Arora, K.; Prakash, S. Microbial medicine: Prebiotic and probiotic functional foods to target obesity and metabolic syndrome. *Int. J. Mol. Sci.* 2020, 21, 2890. [CrossRef]

65. Hjørva, E. Probiotics and prebiotics, targeting obesity with functional foods. *Bratisl. Lek. Listy* 2021, 122, 647–652. [CrossRef] [PubMed]

66. Fuhr Snethlage, C.M.; Nieuwdorp, M.; Hanssen, N.M.J. Faecal microbiota transplantation in endocrine diseases and obesity. *Best Pract. Res. Clin. Endocrinol. Metab.* 2021, 35, 101483. [CrossRef]

67. Pitocco, D.; Di Leo, M.; Tartaglione, L.; De Leva, F.; Petruzziello, C.; Saviano, A.; Pontecorvi, A.; Ojeti, V. The role of gut microbiota in mediating obesity and diabetes mellitus. *Eur. Rev. Med. Pharmacol. Sci.* 2020, 24, 1548–1562. [CrossRef]

68. Boscaín, S.; Leigh, S.J.; Lavelle, A.; García-Cabrero, R.; Lipuma, T.; Clarke, G.; Schellekens, H.; Cryan, J.F. Microbiota and body weight control: Weight watchers within? *Mol. Metab.* 2022, 57, 101427. [CrossRef]

69. Giralt, M.; Villarroya, F. White, brown, beige/brite: Different adipose cells for different functions? *Endocrinology* 2013, 154, 2992–3000. [CrossRef]

70. Sacks, H.; Symonds, M.E. Anatomical locations of human brown adipose tissue: Functional relevance and implications in obesity and type 2 diabetes. *Diabetes* 2013, 62, 1783–1790. [CrossRef]

71. Chen, Y.; Pan, R.; Pfeifer, A. Fat tissues, the brite and the dark sides. *Pflug. Arch. Eur. J. Physiol.* 2016, 468, 1803–1807. [CrossRef]

72. Matsuzawa, Y. Adipocytokines and metabolic syndrome. *Semin. Vasc. Med.* 2005, 5, 34–39. [CrossRef]

73. Fasshauer, M.; Blüher, M. Adipokines in health and disease. *Trends Pharmacol. Sci.* 2015, 36, 461–470. [CrossRef]

74. Ibrahim, M.M. Subcutaneous and visceral adipose tissue: Structural and functional differences. *Obes. Rev.* 2010, 11, 11–18. [CrossRef]

75. Després, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. *Nature* 2006, 444, 881–887. [CrossRef]

76. Hill, J.H.; Solt, C.; Foster, M.T. Obesity associated disease risk: The role of inherent differences and location of adipose depots. *Horm. Mol. Biol. Clin. Investig.* 2018, 33, 20180012. [CrossRef]

77. Karpe, F.; Pinnick, K.E. Biology of upper-body and lower-body adipose tissue–link to whole-body phenotypes. *Nat. Rev. Endocrinol.* 2015, 11, 90–100. [CrossRef]

78. Piché, M.E.; Tchernof, A.; Després, J.P. Obesity phenotypes, diabetes, and cardiovascular diseases. *Circ. Res.* 2020, 127, e107. [CrossRef]
Cells 2022, 11, 1883

79. Cotillard, A.; Poitou, C.; Torcivia, A.; Bouillot, J.L.; Dietrich, A.; Klötting, N.; Grégoire, C.; Lolmede, K.; Blüher, M.; Clément, K. Adipocyte size threshold matters: Link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J. Clin. Endocrinol. Metab. 2014, 99, E1466–E1470. [CrossRef]

80. Hotamisligil, G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140, 900–917. [CrossRef]

81. Boden, G.; Duan, X.; Homko, C.; Molina, E.J.; Song, W.; Perez, O.; Cheung, P.; Merali, S. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008, 57, 2438–2444. [CrossRef]

82. Michailidou, Z. Fundamental roles for hypoxia signalling in adipose tissue metabolism and inflammation in obesity. Curr. Opin. Physiol. 2019, 12, 39–43. [CrossRef]

83. Michailidou, Z. Fundamental roles for hypoxia signalling in adipose tissue metabolism and inflammation in obesity. Curr. Opin. Physiol. 2019, 12, 39–43. [CrossRef]

84. Inouye, K.E.; Shi, H.; Howard, J.K.; Daly, C.H.; Lord, G.M.; Rollins, B.J.; Flier, J.S. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007, 56, 2242–2250. [CrossRef]

85. Chung, K.J.; Chatzigeorgiou, A.; Economopoulou, M.; Garcia-Martin, R.; Alexaki, V.I.; Mitroulis, I.; Nati, M.; Gebler, J.; Ziemssen, T.; Goelz, S.E.; et al. A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity. Nat. Immunol. 2017, 18, 654–664. [CrossRef]

86. Braune, J.; Weyer, U.; Hobusch, C.; Mauer, J.; Brüning, J.C.; Bechmann, I.; Gericke, M. IL-6 regulates M2 polarization and local proliferation of adipose tissue macrophages in obesity. J. Immunol. 2017, 198, 2927–2934. [CrossRef]

87. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 2007, 117, 175–184. [CrossRef]

88. Shaul, M.E.; Bennett, G.; Strissel, K.J.; Greenberg, A.S.; Obin, M.S. Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet-induced obesity in mice. Diabetes 2010, 59, 1171–1181. [CrossRef]

89. Hill, A.A.; Reid Bolus, W.; Hasty, A.H. A decade of progress in adipose tissue macrophage biology. Immunol. Rev. 2014, 262, 134–152. [CrossRef]

90. Suganami, T.; Tanimoto-Koyama, K.; Nishida, J.; Itoh, M.; Yuan, X.; Mizuarai, S.; Kotani, H.; Yamaoka, S.; Miyake, K.; Aoe, S.; et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 84–91. [CrossRef]

91. Suganami, T.; Nishida, J.; Ogawa, Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2062–2068. [CrossRef] [PubMed]

92. Erridge, C.; Samani, N.J. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1944–1949. [CrossRef] [PubMed]

93. Pal, D.; Dasgupta, S.; Kundu, R.; Maitra, S.; Das, G.; Mukhopadhyay, S.; Ray, S.; Majumdar, S.S.; Bhattacharya, S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 2012, 18, 1279–1285. [CrossRef] [PubMed]

94. Engin, A. The pathogenesis of obesity-associated adipose tissue inflammation. Adv. Exp. Med. Biol. 2017, 960, 221–245. [CrossRef] [PubMed]

95. Russo, L.; Lumeng, C.N. Properties and functions of adipose tissue macrophages in obesity. Immunology 2018, 155, 407–417. [CrossRef]

96. Lee, B.C.; Lee, J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim. Biophys. Acta 2014, 1842, 446–462. [CrossRef]

97. Suganami, T.; Ogawa, Y. Adipose tissue macrophages: Their role in adipose tissue remodeling. J. Leukoc. Biol. 2010, 88, 33–39. [CrossRef]

98. Asghar, A.; Sheikh, N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell. Immunol. 2017, 315, 18–26. [CrossRef]

99. Liew, P.X.; Kubes, P. The neutrophil’s role during health and disease. Physiol. Rev. 2019, 99, 1223–1248. [CrossRef]

100. Fine, N.; Tasevska, N.; McCulloch, C.A.; Tenenbaum, H.C.; Glogauer, M. The neutrophil: Constant defender and first responder. Front. Immunol. 2020, 11, 571085. [CrossRef]

101. Uribe-Querol, E.; Rosales, C. Phagocytosis: Our current understading of a universal biological process. Front. Immunol. 2020, 11, 1066. [CrossRef]

102. Rosales, C.; Lowell, C.A.; Schnoor, M.; Uribe-Querol, E. Neutrophils: Their role in innate and adaptive immunity 2017. J. Immunol. Res. 2017, 2017, 9748345. [CrossRef] [PubMed]

103. Rosales, C.; Uribe-Querol, E. Phagocytosis: A fundamental process in immunity. BioMed Res. Int. 2017, 2017, 9042851. [CrossRef] [PubMed]

104. Tecchio, C.; Cassatella, M.A. Neutrophil-derived chemokines on the road to immunity. Semin. Immunol. 2016, 28, 119–128. [CrossRef] [PubMed]

105. Rosales, C. Neutrophils at the crossroads of innate and adaptive immunity. J. Leukoc. Biol. 2020, 108, 377–396. [CrossRef]

106. Tsai, C.Y.; Hsieh, S.C.; Liu, C.W.; Lu, C.S.; Wu, C.H.; Liao, H.T.; Chen, M.H.; Li, K.J.; Shen, C.Y.; Kuo, Y.M.; et al. Cross-talk among polymorphonuclear neutrophils, immune, and non-Immune cells via released cytokines, granule proteins, microvesicles, and neutrophil extracellular trap formation: A novel concept of biology and pathobiology for neutrophils. Int. J. Mol. Sci. 2021, 22, 3119. [CrossRef]
107. Herishanu, Y.; Rogowski, O.; Polliacl, A.; Marius, R. Leukocytosis in obese individuals: Possible link in patients with unexplained persistent neutrophilia. Eur. J. Haematol. 2006, 76, 516–520. [CrossRef]

108. Kim, J.A.; Park, H.S. White blood cell count and abdominal fat distribution in female obese adolescents. Metab. Clin. Exp. 2008, 57, 1375–1379. [CrossRef]

109. Weir, A.B.; Lewis, J.B., Jr.; Arteta-Bulos, R. Chronic idiopathic neutrophilia: Experience and recommendations. South. Med. J. 2011, 104, 499–504. [CrossRef]

110. Rhe, H.; Love, T.; Harrington, D. Blood neutrophil count is associated with body mass index in adolescents with asthma. JSM Allergy Asthma 2018, 3, 1019.

111. Gallego-Suárez, C.; Bulan, A.; Hirschfeld, E.; Wachowiak, P.; Atrashhmi, S.; Griffin, C.; Sturza, J.; Tzau, A.; Hayes, T.; Woolford, S.J.; et al. Enhanced myeloid leukocytes in obese children and adolescents at risk for metabolic impairment. Front. Endocrinol. 2020, 11, 327. [CrossRef]

112. Zernecke, A.; Bot, I.; Djalali-Talab, Y.; Shagdrasuren, E.; Bidzhekov, K.; Meiler, S.; Krohn, R.; Schober, A.; Sperandio, M.; Soehnlein, O.; et al. Protective role of CXCR receptor 4/CXCR ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res. 2008, 102, 209–217. [CrossRef] [PubMed]

113. Ali, M.; Jasmin, S.; Fariduddin, M.; Alam, S.M.K.; Arslan, M.I.; Biswas, S.K. Neutrophil elastase and myeloperoxidase mRNA expression in overweight and obese subjects. Mol. Biol. Rep. 2018, 45, 1245–1252. [CrossRef] [PubMed]

114. Roberts, H.M.; Grant, M.M.; Hubner, N.; Super, P.; Singhal, R.; Chapelle, I.L.C. Impact of bariatric surgical intervention on peripheral blood neutrophil (PNB) function in obesity. Obes. Surg. 2018, 28, 1611–1621. [CrossRef] [PubMed]

115. Dixon, J.B.; O’Brien, P.E. Obesity and the white blood cell count: Changes with sustained weight loss. Obes. Surg. 2006, 16, 251–257. [CrossRef]

116. Festa, A.; D’Agostino, R., Jr.; Williams, K.; Karter, A.J.; Tracy, R.P.; Haffner, S.M. The relation of body fat mass and distribution to markers of chronic inflammation. Int. J. Obes. Relat. Metab. Disord. 2001, 25, 1407–1415. [CrossRef]

117. Bruun, J.M.; Pedersen, S.B.; Richelsen, B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J. Clin. Endocrinol. Metab. 1998, 86, 1267–1273. [CrossRef]

118. Hotamisligil, G.S.; Arner, P.; Caro, J.F.; Atkinson, R.L.; Spiegelman, B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Investig. 1995, 95, 2409–2415. [CrossRef]

119. Hotamisligil, G.S.; Shargil, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993, 259, 87–91. [CrossRef]

120. Kern, P.A.; SaghiZadeh, M.; Ong, J.M.; Bosch, R.J.; Deem, R.; SimSolo, R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Investig. 1995, 95, 2111–2119. [CrossRef]

121. Mohamed-Ali, V.; Goodrick, S.; Rawesh, A.; Katz, D.R.; Miles, J.M.; Yudkin, J.S.; Klein, S.; Coppack, S.W. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 1997, 82, 4196–4200. [CrossRef]

122. Zhang, H.H.; Kumar, S.; Barnett, A.H.; Eggo, M.C. Dexamethasone inhibits tumor necrosis factor-alpha-induced apoptosis and interleukin-1 beta release in human subcutaneous adipocytes and preadipocytes. J. Clin. Endocrinol. Metab. 2001, 86, 2817–2825. [CrossRef] [PubMed]

123. Rusten, L.S.; Jacobsen, F.W.; Lesslauer, W.; Loetscher, H.; Smeland, E.B.; Jacobsen, S.E. Bifunctional effects of tumor necrosis factor receptors. Blood 1994, 83, 3152–3159. [CrossRef] [PubMed]

124. Sieff, C.A.; Niemeyer, C.M.; Mentzer, S.J.; Faller, D.V. Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood 1988, 72, 1316–1323. [CrossRef]

125. Veltri, S.; Smith, J.W., 2nd. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects. Stem Cells 1996, 14, 164–176. [CrossRef] [PubMed]

126. Suwa, T.; Hogg, J.C.; English, D.; Van Eeden, S.F. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am. J. Physiol. Heart Circ. Physiol. 2000, 279, H2954–H2960. [CrossRef] [PubMed]

127. Bruno, A.; Conus, S.; Schmid, I.; Simon, H.U. Apoptotic pathways are inhibited by leptin receptor activation in neutrophils. J. Immunol. 2005, 174, 8090–8096. [CrossRef]

128. Claycombe, K.; King, L.E.; Fraker, P.J. A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proc. Natl. Acad. Sci. USA 2008, 105, 2017–2021. [CrossRef]

129. Laherrague, P.; Oppert, J.M.; Brousset, P.; Charlet, J.P.; Campfield, A.; Fontanilles, A.M.; Guy-Grand, B.; Corberand, J.X.; Pénicaud, L.; Castella, L. High concentration of leptin stimulates myeloid differentiation from human bone marrow CD34+ progenitors: Potential involvement in leukocytosis of obese subjects. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 1212–1216. [CrossRef]

130. Zahorec, R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl. Lek. Listy 2021, 122, 474–488. [CrossRef]

131. Keskin, Kurt, R.; Okyay, A.G.; Hakverdi, A.U.; Gungoren, A.; Dolapcioglu, K.S.; Karateke, A.; Dogan, M.O. The effect of obesity on inflammatory markers in patients with PCOS: A BMI-matched case-control study. Arch. Gynecol. Obstet. 2014, 290, 315–319. [CrossRef]

132. Aydin, M.; Yilmaz, A.; Donna, M.M.; Tulubas, F.; Demirkol, M.; Erdogan, M.; Gurel, A. Neutrophil/lymphocyte ratio in obese adolescents. North. Clin. Istanb. 2015, 2, 87–91. [CrossRef]
133. Fang, Q.; Tong, Y.W.; Wang, G.; Zhang, N.; Chen, W.G.; Li, Y.F.; Shen, K.W.; Wu, B.W.; Chen, X.S. Neutrophil-to-lymphocyte ratio, obesity, and breast cancer risk in Chinese population. *Medicine* 2018, 97, e11692. [CrossRef]

134. Kain, V.; Van Der Pol, W.; Mariappan, N.; Ahmad, A.; Eipers, P.; Gibson, D.L.; Gladine, C.; Vigor, C.; Durand, T.; Morrow, C.; et al. Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil:lymphocyte ratio, leading to impaired milieu in acute heart failure. *FASEB J.* 2019, 33, 6456–6469. [CrossRef]

135. Čalıb, V.; Latza, C.; Creț, V.; Răcătăianu, N.; Iancu, M.; Bolboacă, S.D. Inflammation-related markers and thyroid function measures in pediatric patients: Is the grade of obesity relevant? *Diagnoses* 2021, 11, 485. [CrossRef]

136. Eren, C.; Cecen, S. The relationship between childhood obesity with inflammatory mediator. *J. Pak. Med. Assoc.* 2020, 70, 1737–1741. [CrossRef]

137. Marginean, C.O.; Miliț, L.E.; Huțuțu, A.; Ghiga, D.V.; Săsăran, M.O. The gap between overweight and obesity status in children—(STROBE-compliant article). *Medicine* 2021, 100, e24520. [CrossRef]

138. Orlandini, L.F.; Pimentel, F.F.; Andrade, J.M.; Reis, F.J.C.D.; Mattos-Arruda, L.; Tietze, D.G. Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients. *Braz. J. Med. Biol. Res.* 2021, 54, e11409. [CrossRef]

139. Trelakis, S.; Rydeulskaaya, A.; Fischer, C.; Canbay, A.; Tagay, S.; Scherag, A.; Bruderek, K.; Schuler, P.J.; Brandau, S. Low adiponectin, high levels of apoptosis and increased peripheral blood neutrophil activity in healthy obese subjects. *Obes. Facts* 2012, 5, 305–318. [CrossRef]

140. Osadnik, T.; Bujak, K.; Osadnik, K.; Czarnecka, H.; Pawlas, N.; Regula, R.; Fronzek, M.; Lejawa, M.; Gawlita, M.; Gonera, M.; et al. Novel inflammatory biomarkers may reflect subclinical inflammation in young healthy adults with obesity. *Endokrynol. Pol.* 2019, 70, 135–142. [CrossRef]

141. Rodríguez-Rodriguez, E.; López-Sobaler, A.M.; Ortega, R.M.; Delgado-Losada, M.L.; López-Parra, A.M.; Aparicio, A. Association between neutrophil-to-lymphocyte ratio with abdominal obesity and healthy eating index in a representative older Spanish population. *Nutrients* 2020, 12, 855. [CrossRef]

142. Suárez-Cuenca, J.A.; Ruiz-Hernández, A.S.; Mendoza-Castañeda, A.A.; Domínguez-Pérez, G.A.; Hernández-Patricio, A.; Vera-Gómez, E.; De la Peña-Sosa, G.; Banderas-Lares, D.Z.; Montoya-Ramirez, J.; Blas-Azotila, R.; et al. Neutrophil-to-lymphocyte ratio and its relation with pro-inflammatory mediators, visceral adiposity and carotid intima-media thickness in population with obesity. *Eur. J. Clin. Investig.* 2019, 49, e13085. [CrossRef]

143. Yilmaz, H.; Ucan, B.; Sayki, M.; Unsal, I.; Sahin, M.; Ozbek, M.; Delibasi, T. Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity. *Diabetes Metab. Syndr.* 2015, 9, 299–304. [CrossRef]

144. Ferrante, A.W., Jr. The immune cells in adipose tissue. *Diabetes Obes. Metab.* 2013, 15, 34–38. [CrossRef]

145. Skinner, A.C.; Steiner, M.J.; Henderson, F.W.; Perrin, E.M. Multiple markers of inflammation and weight status: Cross-sectional analyses throughout childhood. *Pediatrics* 2010, 125, e801–e809. [CrossRef]

146. Mantovani, A.; Cassatella, M.A.; Constantini, C.; Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat. Rev. Immunol.* 2011, 11, 519–531. [CrossRef]

147. Talukdar, S.; Oh, D.Y.; Bandyopadhyay, G.; Li, D.; Xu, J.; McNelis, J.; Lu, M.; Li, P.; Yan, Q.; Zhu, Y.; et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. *Nat. Med.* 2012, 18, 1407–1412. [CrossRef]

148. Girbl, T.; Lenn, T.; Perez, L.; Rolas, L.; Barkaway, A.; Thiriot, A.; Del Fresno, C.; Lynam, E.; Hub, E.; Thelen, M.; et al. Distinct compartmentalization of the chemokines CXCL1 and CXCL2 and the atypical receptor ACKR1 determine discrete stages of neutrophil diapedesis. *Nat. Immunol.* 2018, 19, 49, 1062–1076. [CrossRef]

149. Tynan, G.A.; Hearnden, C.H.; Oleszycka, E.; Lyons, C.L.; Coutts, G.; O’Connell, J.; Corrigan, M.A.; Lynch, L.; Campbell, M.; Callanan, J.J.; et al. Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1α-dependent inflammation. *Diabetes* 2014, 63, 2037–2050. [CrossRef]

150. Dam, V.; Sidker, T.; Santos, S. From neutrophils to macrophages: Differences in regional adipose tissue depots. *Obes. Rev.* 2016, 17, 1–17. [CrossRef]

151. Trim, W.; Turner, J.E.; Thompson, D. Parallels in immunometabolic adipose tissue dysfunction with ageing and obesity. *Front. Immunol.* 2018, 9, 169. [CrossRef]

152. Mansuy-Aubert, V.; Zhou, Q.L.; Xie, X.; Gong, Z.; Huang, J.Y.; Khan, A.R.; Aubert, G.; Candelaria, K.; Thomas, S.; Shin, D.J.; et al. Imbalance between neutrophil elastase and its inhibitor α1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. *Cell Metab.* 2013, 17, 534–548. [CrossRef]

153. Hotamisligil, G.S. Foundations of immunometabolism and implications for metabolic health and disease. *Immunity* 2017, 47, 406–420. [CrossRef] [PubMed]

154. Vandana, B.; Youm, Y.H.; Ravussin, A.; Galgani, J.E.; Stadler, K.; Mynatt, R.L.; Ravussin, E.; Stephens, J.M.; Dixit, V.D. The NLRP3 inflammasome instigates inflammation and insulin resistance. *Nat. Med.* 2011, 17, 179–188. [CrossRef]

155. Wiersma, J.J.; Meuwese, M.C.; van Miert, J.N.; Kastelein, A.; Tijssen, J.G.; Piek, J.J.; Trip, M.D. Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. *Med. Sci. Monit.* 2008, 14, CR406–CR410.

156. Sun, Z.; Dragon, S.; Becker, A.; Gounni, A.S. Leptin inhibits neutrophil apoptosis in children via ERK/ NF-κB-dependent pathways. *PLoS ONE* 2013, 8, e55249. [CrossRef]
157. Bosco, A.M.; Almeida, B.F.M.; Valadares, T.C.; Baptistioli, L.; Hoffmann, D.J.; Pereira, A.A.F.; Lima, V.M.F.; Ciarlini, P.C. Preactivation of neutrophils and systemic oxidative stress in dogs with hyperleptinemia. *Vet. Immunol. Immunopathol.* **2018**, *202*, 18–24. [CrossRef]

158. Salinas, C.; Espinosa, G.; Morales, N.; Henriquez, C.; Morán, G.; Gajardo, G.; Uberti, B. Assessment of peripheral blood neutrophil respiratory burst, phagocytosis and apoptosis in obese non-insulin dysregulated horses. *Res. Vet. Sci.* **2020**, *132*, 127–132. [CrossRef]

159. Wilson, R.M.; Reeves, W.G. Neutrophil phagocytosis and killing in insulin-dependent diabetes. *Clin. Exp. Immunol.* **1986**, *63*, 478–484.

160. Mancuso, P.; Curtis, J.L.; Weitzel, A.M.; Griffin, C.A.; Bouchard, B.; Freeman, C.M.; Bridges, D.; Singer, K. Diet-induced obesity in mice impairs host defense against Klebsiella pneumonia in vivo and glucose transport and bactericidal functions in neutrophils in vitro. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2022**, *322*, L116–L128. [CrossRef]

161. Dobner, J.; Kaser, S. Body mass index and the risk of infection—From underweight to obesity. *Clin. Microbiol. Infect.* **2018**, *24*, 24–28. [CrossRef]

162. Frydrych, L.M.; Bian, G.; O’Lone, D.E.; Ward, P.A.; Delano, M.J. Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. *J. Leukoc. Biol.* **2018**, *104*, 525–534. [CrossRef]

163. Amulic, B.; Cazalet, C.; Hayes, G.L.; Metzler, K.D.; Zychlinsky, A. Neutrophil function: From mechanisms to disease. *Annu. Rev. Immunol.* **2012**, *30*, 459–489. [CrossRef]

164. Soehnlein, O.; Zernecke, A.; Eriksson, E.E.; Rothfuchs, A.G.; Pham, C.T.; Herwald, H.; Bidzhekov, K.; Rottenberg, M.E.; Weber, C.; Lindbom, L. Neutrophil secretion products pave the way for inflammatory monocytes. *Blood* **2008**, *112*, 1461–1471. [CrossRef]

165. Soehnlein, O.; Lindbom, L.; Weber, C. Mechanisms underlying neutrophil-mediated monocye recruitment. *Blood* **2008**, *114*, 4613–4623. [CrossRef]

166. Gao, C.H.; Dong, H.L.; Tai, L.; Gao, X.M. Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2- into M1-like phenotype. *Front. Immunol.* **2018**, *9*, 37. [CrossRef]

167. Xing, L.; Zhongqian, L.; Chunmei, S.; Pingfa, C.; Lei, H.; Qin, J.; Genhua, M.; Yijun, D. Activation of M1 macrophages in sepsis-induced acute kidney injury in response to heparin-binding protein. *PLoS ONE* **2018**, *13*, e0196423. [CrossRef]

168. Soehnlein, O.; Kai-Larsen, Y.; Frithiof, R.; Sorensen, O.E.; Kenne, E.; Scharffetter-Kochanek, K.; Eriksson, E.E.; Herwald, H.; Agerberth, B.; Lindbom, L. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. *J. Clin. Investig.* **2008**, *118*, 3491–3502. [CrossRef]

169. Ribon, M.; Seninet, S.; Mussard, J.; Sebbag, M.; Clavel, C.; Serre, G.; Boissier, M.C.; Semerano, L.; Decker, P. Neutrophil extracellular traps exert both pro- and anti-inflammatory actions in rheumatoid arthritis that are modulated by C1q and LL-37. *J. Autoimmun.* **2019**, *98*, 122–131. [CrossRef]

170. van den Bosch, M.H.; Blom, A.B.; Schelbergen, R.F.; Koenders, M.I.; van den Berg, W.B.; Vogl, T.; Roth, J.; van der Kraan, P.M.; van Lent, P.L. Alarmin S100A9 induces proinflammatory and catabolic effects predominantly in the M1 macrophages of human osteoarthritic synovium. *J. Rheumatol.* **2016**, *43*, 1874–1884. [CrossRef]

171. Castanheira, F.V.S.; Kubes, P. Neutrophils and NETs in modulating acute and chronic inflammation. *Blood* **2019**, *133*, 2178–2185. [CrossRef]

172. Papayannopoulo, V. Neutrophil extracellular traps in immunity and disease. *Nat. Rev. Immunol.* **2018**, *18*, 134–147. [CrossRef] [PubMed]

173. Wang, H.; Wang, Q.; Venugopal, J.; Wang, J.; Kleiman, K.; Guo, C.; Eitzman, D.T. Obesity-induced endothelial dysfunction is prevented by neutrophil extracellular trap inhibition. *Sci. Rep.* **2018**, *8*, 4881. [CrossRef] [PubMed]

174. D’Abbondanza, M.; Martorelli, E.E.; Ricci, M.A.; De Vuono, S.; Migliola, E.N.; Godino, C.; Corradetti, S.; Siepi, D.; Paganelli, M.T.; Maugeri, N.; et al. Increased plasmatic NETs by-products in patients in severe obesity. *Sci. Rep.* **2019**, *9*, 14678. [CrossRef] [PubMed]

175. Valeria Oliveira de Sousa, B.; de Freitas, D.F.; Monteiro-Junior, R.S.; Mendes, I.H.R.; Sousa, J.N.; Guimarães, V.H.D.; Santos, S.H.S. Physical exercise, obesity, inflammation and neutrophil extracellular traps (NETs): A review with bioinformatics analysis. *Mol. Biol. Rep.* **2021**, *48*, 4625–4635. [CrossRef] [PubMed]

176. Freitas, D.F.; Colón, D.F.; Silva, R.L.; Santos, E.M.; Guimarães, V.H.D.; Ribeiro, G.H.M.; de Paula, A.M.B.; Guimarães, A.L.S.; Dos Reis, S.T.; Cunha, F.Q.; et al. Neutrophil extracellular traps (NETs) modulate inflammatory profile in obese humans and mice: Adipose tissue role on NETs levels. *Mol. Biol. Rep.* **2022**, *49*, 3225–3236. [CrossRef]

177. Cichon, I.; Ortmann, W.; Santocki, M.; Opdyco-Chanek, M.; Kolaczkowska, E. Scrutinizing mechanisms of the ‘obesity paradox in sepsis’: Obesity is accompanied by diminished formation of neutrophil extracellular traps (NETs) due to restricted neutrophil-platelet interactions. *Cells* **2021**, *10*, 384. [CrossRef]

178. Carestia, A.; Frechhell, G.; Cerrone, G.; Linari, M.A.; Gonzalez, C.D.; Casais, P.; Schattner, M. NETosis before and after hyperglycemic control in type 2 diabetes mellitus patients. *PLoS ONE* **2016**, *11*, e0168647. [CrossRef]

179. Park, J.H.; Kim, J.E.; Gu, J.Y.; Yoo, H.J.; Park, S.H.; Kim, Y.I.; Nam-Goong, I.S.; Kim, E.S.; Kim, H.K. Evaluation of circulating markers of neutrophil extracellular trap (NET) formation as risk factors for diabetic retinopathy in a case-control association study. *Exp. Clin. Endocrinol. Diabetes* **2016**, *124*, 557–561. [CrossRef]

180. Wang, L.; Zhou, X.; Yin, Y.; Mai, Y.; Wang, D.; Zhang, X. Hyperglycemia induces neutrophil extracellular traps formation through an NADPH oxidase-dependent pathway in diabetic retinopathy. *Front. Immunol.* **2019**, *9*, 3076. [CrossRef]
181. Menegazzo, L.; Ciciliot, S.; Poncina, N.; Mazzucato, M.; Persano, M.; Bonora, B.; Albiero, D.; Vigili de Kreutzer, S.; Avogaro, A.; Fadini, G.P. NEtosis is induced by high glucose and associated with type 2 diabetes. *Acta Diabetol.* 2015, 52, 497–503. [CrossRef]

182. Jafar, N.; Edriss, H.; Nugent, K. The effect of short-term hyperglycemia on the innate immune system. *Am. J. Med. Sci.* 2016, 351, 201–211. [CrossRef] [PubMed]

183. Joshi, M.B.; Lad, A.; Bharath Prasad, A.S.; Balakrishnan, A.; Ramachandra, L.; Satyamoothy, K. High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation. *FEBS Lett.* 2013, 587, 2241–2246. [CrossRef] [PubMed]

184. Lee, M.K.S.; Sreejit, G.; Nagareddy, P.R.; Murphy, A.J. Attack of the NETs! NETosis primes IL-1β in dendritic cells promotes autoreactive CD8+ T cell activation via cross-presentation in type 1 diabetes. *JCI Insight* Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *Diabetes Rev.* 2017, 31–55. [CrossRef] [PubMed]

185. Yang, C.T.; Chen, L.; Chen, W.L.; Li, N.; Chen, M.J.; Li, X.; Zheng, X.; Zhao, Y.Z.; Wu, Y.X.; Xian, M.; et al. Hydrogen sulfide primes diabetic wound to close through inhibition of NEtosis. *Mol. Cell. Endocrinol.* 2019, 480, 74–82. [CrossRef]

186. Petersmann, A.; Müller-Wieland, D.; Müller, U.A.; Landgraf, R.; Nauck, M.; Freckmann, G.; Heinemann, L.; Schleicher, E. Definition, classification and diagnosis of diabetes mellitus. *Exp. Clin. Endocrinol. Diabetes* 2019, 127, S1–S7. [CrossRef] [PubMed]

187. World Health Organization. Diabetes (Fact Sheet N°312). Available online: https://web.archive.org/web/20130826174444/http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed on 25 January 2022).

188. Lee, M.K.S.; Sreejit, G.; Nagareddy, P.R.; Murphy, A.J. Attack of the NETs! NETosis primes IL-1β-mediated inflammation in diabetic foot ulcers. *Clin. Sci.* 2020, 139, 1344–1390. [CrossRef]

189. Liu, C.; Whitten, R.L.; Lin, A.; Xu, Y.; Chen, J.; Savinov, A.; Leiding, J.W.; Wallet, M.A.; Mathews, C.E. Neutrophil cytosolic factor 1 in dendritic cells promotes autoreactive CD8+ T cell activation via cross-presentation in type 1 diabetes. *Front. Immunol.* 2019, 10, 952. [CrossRef]

190. Rodriguez-Espinosa, O.; Rojas-Espinosa, O.; Moreno-Altamirano, M.M.; López-Villegas, E.O.; Sánchez-García, F.J. Metabolic requirements for neutrophil extracellular traps formation. *Immunology* 2015, 145, 213–224. [CrossRef]

191. Cichon, I.; Ortman, W.; Kolaczekowska, E. Metabolic pathways involved in formation of spontaneous and lipopolysaccharide-induced neutrophil extracellular traps (NETs) differ in obesity and systemic Inflammation. *Int. J. Mol. Sci.* 2021, 22, 7718. [CrossRef]

192. Petersmann, A.; Müller-Wieland, D.; Müller, U.A.; Landgraf, R.; Nauck, M.; Freckmann, G.; Heinemann, L.; Schleicher, E. Definition, classification and diagnosis of diabetes mellitus. *Exp. Clin. Endocrinol. Diabetes* 2019, 127, S1–S7. [CrossRef] [PubMed]

193. Rohn, T.V.; Meier, D.T.; Olfesky, J.M.; Donath, M.Y. Inflammation in obesity, diabetes, and related disorders. *Immunity* 2022, 55, 31–55. [CrossRef] [PubMed]

194. Bollyky, J.B.; Xu, P.; Butte, A.J.; Wilson, D.M.; Beam, C.A.; Greenbaum, C.J.; Type 1 Diabetes TrialNet Study Group. Heterogeneity in recent-onset type 1 diabetes—A clinical trial perspective. *Diabetes/ Metab. Res. Rev.* 2015, 31, 588–594. [CrossRef] [PubMed]

195. Demir, S.; Nawroth, P.P.; Herzig, S.; Ekm Eusté, B. Emerging targets in type 2 diabetes and diabetic complications. *Adv. Sci.* 2021, 8, e2100275. [CrossRef] [PubMed]

196. Sreejit, G.; Nagareddy, P.R.; Murphy, A.J. Attack of the NETs! NETosis primes IL-1β-mediated inflammation in diabetic foot ulcers. *Clin. Sci.* 2020, 139, 1344–1390. [CrossRef]

197. Lofty, M.; Adeghe, J.; Kalasz, H.; Singh, J.; Adeghe, E. Chronic complications of diabetes mellitus: A mini review. *Curr. Diabetes Rev.* 2017, 13, 3–10. [CrossRef] [PubMed]

198. Rohm, T.V.; Meier, D.T.; Olfesky, J.M.; Donath, M.Y. Inflammation in obesity, diabetes, and related disorders. *Immunity* 2022, 55, 31–55. [CrossRef] [PubMed]

199. Chen, Y.G.; Mathews, C.E.; Driver, J.P. The role of NOD mice in type 1 diabetes research: Lessons from the past and recommendations for the future. *Front. Endocrinol.* 2018, 9, 51. [CrossRef]

200. Miao, D.; Yu, L.; Eisenbarth, G.S. Role of autoantibodies in type 1 diabetes. *Front. Biosci.* 2007, 12, 1889–1898. [CrossRef]

201. Kawasaki, E. Type 1 diabetes and autoimmunity. *Clin. Pediatr. Endocrinol.* 2014, 23, 99–105. [CrossRef]

202. Diana, J.; Simon, Y.; Furio, L.; Beauvoin, L.; Agerberth, B.; Barrat, F.; Lehuem, A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. *Nat. Med.* 2013, 19, 65–73. [CrossRef]

203. Valle, A.; Giamporcaro, G.M.; Scavini, M.; Stabilini, A.; Grogan, P.; Bianconi, E.; Sestaini, G.; Masini, M.; Magueri, N.; Porretti, L.; et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes* 2013, 62, 2072–2077. [CrossRef] [PubMed]

204. Harsunen, M.H.; Puff, R.; D’Orlando, O.; Giannopoulou, E.; Lachmann, L.; Beyerlein, A.; von Meyer, A.; Ziegler, A.G. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. *Horm. Metab. Res.* 2013, 45, 467–470. [CrossRef] [PubMed]

205. Salami, F.; Lee, H.S.; Freyhult, E.; Elding Larsson, H.; Lemmark, A.; Törn, C.; TEDDY Study Group. Reduction in white blood cell, neutrophil, and red blood cell counts related to sex, HLA, and islet autoantibodies in Swedish TEDDY children at increased risk for type 1 diabetes. *Diabetes* 2018, 67, 2329–2336. [CrossRef] [PubMed]

206. Vecchio, F.; Lo Buono, N.; Stabilini, A.; Nigl, L.; Dufort, M.J.; Geyer, S.; Rancoita, P.M.; Cugnata, F.; Mandelli, A.; Valle, A.; et al. Abnormal neutrophil signature in the blood and pancreas of symptomatic and asymptomatic type 1 diabetes. *JCI Insight* 2018, 3, e122146. [CrossRef]
Cells 2022, 11, 1883

207. Huang, J.; Xiao, Y.; Zheng, P.; Zhou, W.; Wang, Y.; Huang, G.; Xu, A.; Zhou, Z. Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes/Metab. Res. Rev. 2019, 35, e3064. [CrossRef]

208. Klocperk, A.; Petruzelkova, L.; Pavlikova, M.; Rataj, M.; Kayserova, J.; Pruhova, S.; Kolouskova, S.; Sklenarova, J.; Parackova, Z.; Sediva, A.; et al. Changes in innate and adaptive immunity over the first year after the onset of type 1 diabetes. Acta Diabetol. 2020, 57, 297–307. [CrossRef]

209. Qin, J.; Fu, S.; Speake, C.; Greenbaum, C.J.; Odegard, J.M. NETosis-associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count. Clin. Exp. Immunol. 2016, 184, 318–322. [CrossRef]

210. Dufort, M.J.; Greenbaum, C.J.; Speake, C.; Linsley, P.S. Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. JCI Insight 2019, 4, e125556. [CrossRef]

211. Shu, L.; Zhong, L.; Xiao, Y.; Wu, X.; Liu, Y.; Jiang, X.; Tang, T.; Hoo, R.; Zhou, Z.; Xu, A. Neutrophil elastase triggers the development of autoimmune diabetes by exacerbating innate immune responses in pancreatic islets of non-obese diabetic mice. Clin. Sci. 2020, 134, 1679–1696. [CrossRef]

212. Garciafigueroa, Y.; Phillips, B.E.; Engman, C.; Trucco, M.; Giannoukakis, N. Neutrophil-associated inflammatory changes in the pre-diabetic pancreas of early-age NOD mice. Front. Endocrinol. 2021, 12, 565981. [CrossRef] [PubMed]

213. Németh, T.; Mócsai, A. The role of neutrophils in autoimmune diseases. Immunol. Lett. 2012, 143, 9–19. [CrossRef] [PubMed]

214. Wang, Y.; Xiao, Y.; Zhong, L.; Ye, D.; Zhang, J.; Tu, Y.; Bornstein, S.R.; Zhou, Z.; Lam, K.S.; Xu, A. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with β-cell autoimmunity in patients with type 1 diabetes. Diabetes 2014, 63, 4239–4248. [CrossRef] [PubMed]

215. Njeim, R.; Azar, W.S.; Fares, A.H.; Azar, S.T.; Kfoury Kassouf, H.; Eid, A.A. NETosis contributes to the pathogenesis of diabetes and its complications. J. Mol. Endocrinol. 2020, 65, R56–R76. [CrossRef] [PubMed]

216. Sodrê, F.M.C.; Bissenova, S.; Bruggeman, Y.; Tilvawala, R.; Cook, D.P.; Berthault, C.; Mondal, S.; Callebaut, A.; You, S.; Scharffmann, R.; et al. Peptidylarginine deiminase inhibition prevents diabetes development in NOD mice. Diabetes 2021, 70, 516–528. [CrossRef] [PubMed]

217. Parackova, Z.; Zentsova, I.; Vrabcova, P.; Klocperk, A.; Sumnik, Z.; Pruho, S.; Petruzelkova, L.; Hasler, R.; Sediva, A. Neutrophil extracellular trap-induced dendritic cell activation leads to Th1 polarization in type 1 diabetes. Front. Immunol. 2020, 11, 661. [CrossRef]

218. Smulski, C.R.; Eibel, H. BAFF and BAFF-receptor in B cell selection and survival. Front. Immunol. 2018, 9, 2285. [CrossRef]

219. Costa, S.; Bevilacqua, D.; Cassatella, M.A.; Scapini, P. Recent advances on the crosstalk between neutrophils and B or T lymphocytes. Immunology 2019, 159, 23–32. [CrossRef]

220. Cutler, C.W.; Eke, P.; Arnold, R.R.; Van Dyke, T.E. Defective neutrophil function in an insulin-dependent diabetes mellitus patients. A case report. J. Periodontol. 1991, 62, 394–401. [CrossRef] [PubMed]

221. Marhoffer, W.; Stein, M.; Schleinkofer, L.; Federlin, K. Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 1993, 19, 183–188. [CrossRef]

222. Kjersem, H.; Hilsted, J.; Madsbad, S.; Wandall, J.H.; Borregaard, N. Polymorphonuclear leucocyte dysfunction during short term metabolic changes from normo- to hyperglycemia in type 1 (insulin dependent) diabetic patients. Infection 1989, 16, 218–221. [CrossRef] [PubMed]

223. Nielsen, C.P.; Hindson, D.A. Inhibition of polymorphonuclear leucocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 1989, 38, 1031–1035. [PubMed]

224. Khan, M.A.B.; Hashim, M.J.; King, J.K.; Govender, R.D.; Mustafa, H.; Al Kaibi, J. Epidemiology of type 2 diabetes—Global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 2020, 10, 107–111. [CrossRef] [PubMed]

225. Hatanaka, E.; Monteagudo, P.T.; Marrocos, M.S.; Campa, A. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin. Exp. Immunol. 2006, 146, 443–447. [CrossRef]

226. Good, M.; Newell, F.M.; Haupt, L.M.; Whitehead, J.P.; Hutley, L.J.; Prins, J.B. TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue—influence of BMI and adipose distribution. Diabetes Vasc. Dis. Res. 2004, 1, 291–297. [CrossRef]

227. Bilgic Gazioglu, S.; Akan, G.; Atalar, F.; Erten, G. PAI-1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients. Int. J. Clin. Exp. Pathol. 2015, 8, 15919–15925. [CrossRef]

228. Meigs, J.B.; Hu, F.B.; Rifai, N.; Manson, J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291, 1978–1986. [CrossRef]

229. Lee, J.; Lee, S.; Zhang, H.; Hill, M.A.; Zhang, C.; Park, Y. Interaction of IL-6 and TNF-α contributes to endothelial dysfunction in type 2 diabetic mice. PLoS ONE 2017, 12, e0187189. [CrossRef]

230. Tabit, C.E.; Chung, W.B.; Hamburg, N.M.; Vita, J.A. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev. Endocr. Metab. Disord. 2010, 11, 61–74. [CrossRef]
233. Ntaios, G.; Gatselis, N.K.; Makaritsis, K.; Dalekos, G.N. Adipokines as mediators of endothelial function and atherosclerosis. *Atherosclerosis* 2013, 227, 216–221. [CrossRef] [PubMed]

234. Zhang, Y.; Yang, X.; Bian, F.; Wu, P.; Xing, S.; Xu, G.; Li, W.; Chi, J.; Ouyang, C.; Zheng, T.; et al. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: Crosstalk between NF-κB and PPAR-γ. *J. Mol. Cell. Cardiol.* 2014, 72, 85–94. [CrossRef] [PubMed]

235. Huang, H.; Gandhi, J.K.; Zhong, X.; Wei, Y.; Gong, J.; Duh, E.J.; Vinores, S.A. TNF alpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. *Investig. Ophthalmol. Vis. Sci.* 2011, 52, 1336–1344. [CrossRef]

236. Nordmann, T.M.; Droz, E.; Schulze, F.; Traub, S.; Berishvili, E.; Barbieux, C.; Böni-Schnetzler, M.; Donath, M.Y. The role of inflammation in β-cell dedifferentiation. *Sci. Rep.* 2017, 7, 6285. [CrossRef]

237. Talchai, C.; Xuan, S.; Lin, H.V.; Sussel, L.; Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. *Cell* 2012, 150, 1223–1234. [CrossRef] [PubMed]

238. Fainsod-Levi, T.; Gershkovitz, M.; Völs, S.; Kumar, S.; Khawaled, S.; Sagiv, J.Y.; Sionov, R.V.; Grunewald, M.; Keshet, E.; Granot, Z. Hyperglycemia impairs neutrophil mobilization leading to enhanced metastatic seeding. *Cell Rep.* 2017, 21, 2384–2392. [CrossRef]

239. Gomez, I.; Ward, B.; Souilhol, C.; Recarti, C.; Ariaans, M.; Johnston, J.; Burnett, A.; Mahmoud, M.; Luong, L.A.; West, L.; et al. Neutrophil microvesicles drive atherosclerosis by delivering miR-155 to atheroprone endothelium. *Nat. Commun.* 2020, 11, 214. [CrossRef]

240. Rosales, C. Neutrophil: A cell with many roles in inflammation or several cell types? *Front. Physiol.-Integr. Physiol.* 2018, 9, 113. [CrossRef]

241. Chen, P.Y.; Cripps, A.W.; West, N.P.; Cox, A.J.; Zhang, P. A correlation-based network for biomarker discovery in obesity with metabolic syndrome. *BMC Bioinform.* 2019, 20, 477. [CrossRef]